Άρθρα κάπως συναφή με τα ερευνητικά μου ενδιαφέροντα

1. Nouveaux derives de la mescaline
   P. Macheras, G. Tsatsas
   Proceedings of the National Academy of Athens 55, 119-142 (1980)
   
2. Ring opening reactions 1. The triazinone ring opening of 2H-3,4-dihydro-as-triazino [3,4b] benzothiazol-3-one
   M. D. Kazanis, P. E. Macheras
   Chem. Chron. New Ser. 9, 201-205 (1980)
   [PDF]
3. Some considerations concerning the effect of an increased rate of oral absorption on drug levels of protein-bound drugs
   P Macheras, A Rosen
   Int. J. Pharm. 6, 175-178 (1980)
   [DOI: 10.1016/0378-5173(80)90090-3] [PDF]
4. Synthesis of 2-(5'-nitrofurylidene) azino-3-carboxy or carbethoxymethylbenzothiazolines and their activity against some gram-negative bacteria
   MD Kazanis, PE Macheras, NJ Legakis
   Eur. J. Med. Chem. 17, 291-292 (1982)
5. Comparative bioavailability studies of four commercial nitrofurantoin products
   P. E. Macheras
   Chem. Chron. New Ser. 12, 63-73 (1983)
   [PDF]
6. The bioequivalence factor
   P Macheras, A Rosen
   Pharm. Acta Helv. 58, 233-236 (1983)
7. Effect of absorption and elimination rates on the maintenance time of therapeutic drug levels - derivation of an equation for this time and its applications
   P Macheras, A Rosen
   Int. J. Pharm. 16, 353-359 (1983)
   [DOI: 10.1016/0378-5173(83)90155-2] [PDF]
8. The effect of protein on the dissolution of phenytoin
   A Rosen, P Macheras
   J. Pharm. Pharmacol. 36, 723-727 (1984)
   [DOI: 10.1111/j.2042-7158.1984.tb04859.x] [PDF]
9. Glc analysis following oxidation of phenytoin - an inexpensive method for routine determination of the drug in plasma
   P Macheras, A Rosen
   Pharmazie 39, 322-325 (1984)
   [DOI: 10.24355/dbbs.084-201811191154-0][PDF]
10. Is monitoring of drug in saliva reliable for bioavailability testing of a protein-bound drug - a theoretical approach
    P Macheras, A Rosen
    Pharm. Acta Helv. 59, 34-36 (1984)
11. Is monitoring of drug in saliva reliable for bioavailability testing of a protein-bound drug - a theoretical approach
    P Macheras, A Rosen
    Pharm. Acta Helv. 59, 34-36 (1984)
12. Quick method for the calculation of the absorption rate-constant of the linear one-compartment model using all available blood level data
    P Macheras
    Int. J. Pharm. 19, 339-343 (1984)
    [DOI: 10.1016/0378-5173(84)90063-2] [PDF]
13. Application of automated flow-injection analysis (fia) to dissolution studies
    M Koupparis, P Macheras, C Reppas
    Int. J. Pharm. 20, 325-333 (1984)
    [DOI: 10.1016/0378-5173(84)90179-0] [PDF]
14. Effect of protein on the absorption of phenytoin through everted gut preparations
    A Rosen, P Macheras
    J. Pharm. Pharmacol. 37, 154-158 (1985)
    [DOI: 10.1111/j.2042-7158.1985.tb05031.x] [PDF]
15. Milk drug coadministration
    P Macheras, C Reppas
    Pharmacology & Pharmacy 6, 152-153 (1985)
16. Automated flow-injection colorimetric determination of acetaminophen for assays and dissolution studies of multicomponent dosage forms
    M Koupparis, P Macheras, C Tsaprounis
    Int. J. Pharm. 27, 349-359 (1985)
    [DOI: 10.1016/0378-5173(85)90082-1] [PDF]
17. Graphical approach for determining whether absorption and elimination rate constants are equal in the one-compartment open model with 1st-order processes
    PE Macheras
    J. Pharm. Sci. 74, 582-584 (1985)
    [DOI: 10.1002/jps.2600740521] [PDF]
18. Developments in the concentration ratio method
    PE Macheras
    J. Pharm. Sci. 74, 1021-1021 (1985)
    [DOI: 10.1002/jps.2600740927] [PDF]
19. An automated flow injection-serial dynamic dialysis technique for drug protein-binding studies
    P Macheras, M Koupparis, C Tsaprounis
    Int. J. Pharm. 30, 123-132 (1986)
    [DOI: 10.1016/0378-5173(86)90072-4] [PDF]
20. The use of constant volume ultrafiltration for dissolution studies
    A Rosen, P Macheras, KD Howe
    Int. J. Pharm. 32, 171-175 (1986)
    [DOI: 10.1016/0378-5173(86)90176-6] [PDF]
21. Drug dissolution studies in milk using the automated flow-injection serial dynamic dialysis technique
    P Macheras, M Koupparis, C Tsaprounis
    Int. J. Pharm. 33, 125-136 (1986)
    [DOI: 10.1016/0378-5173(86)90046-3] [PDF]
22. Determination of nitrofurantoin in urine by derivative spectroscopy
    M Poulou, P Macheras
    Int. J. Pharm. 34, 29-34 (1986)
    [DOI: 10.1016/0378-5173(86)90006-2] [PDF]
23. Studies on drug milk freeze-dried formulations I. Bioavailability of sulfamethizole and dicumarol formulations
    PE Macheras, CI Reppas
    J. Pharm. Sci. 75, 692-696 (1986)
    [DOI: 10.1002/jps.2600750716] [PDF]
24. An automated flow-injection serial dynamic dialysis technique for drug-protein binding-studies
    PE Macheras, MA Koupparis
    Anal. Chim. Acta 185, 65-73 (1986)
    [DOI: 10.1016/0003-2670(86)80033-2] [PDF]
25. Studies on freeze-dried drug-milk formulations II. Effect of regenerated fluid volume on nitrofurantoin bioavailability
    PE Macheras, CI Reppas
    J. Pharm. Sci. 75, 1145-1150 (1986)
    [DOI: 10.1002/jps.2600751206] [PDF]
26. Method of residuals: Estimation of absorption and elimination rate constants having comparable values
    P. Macheras
    Biopharm. Drug Dispos. 8, 47-56 (1987)
    [DOI: 10.1002/bdd.2510080106] [PDF]
27. Dissolution of 4 controlled-release theophylline formulations in milk
    P Macheras, M Koupparis, E Apostolelli
    Int. J. Pharm. 36, 73-79 (1987)
    [DOI: 10.1016/0378-5173(87)90239-0] [PDF]
28. Dissolution and invitro permeation behaviors of dicumarol nitrofurantoin and sulfamethizole in the presence of protein
    P Macheras, C Reppas
    Int. J. Pharm. 37, 103-112 (1987)
    [DOI: 10.1016/0378-5173(87)90014-7] [PDF]
29. Analysis of linear one compartment open models
    P Macheras, A Rosen
    Am. J. Pharm. Educ. 51, 291-293 (1987)
30. Improvement without computer-assistance of the graphically estimated parameters of the linear one-compartment open model
    PE Macheras
    Biopharm. Drug Dispos. 8, 387-394 (1987)
    [DOI: 10.1002/bdd.2510080409] [PDF]
31. Effect of temperature and fat-content on the binding of hydrochlorothiazide and chlorothiazide to milk
    PE Macheras, MA Koupparis, SG Antimisiaris
    J. Pharm. Sci. 77, 334-336 (1988)
    [DOI: 10.1002/jps.2600770411] [PDF]
32. 2nd derivative UV spectrophotometric determination of hydrochlorothiazide and hydrochlorothiazide amiloride combination in tablets
    M Parissi-Poulou, V Reizopoulou, M Koupparis, P Macheras
    Int. J. Pharm. 51, 169-174 (1989)
    [DOI: 10.1016/0378-5173(89)90251-2] [PDF]
33. An invitro model for exploring CR theophylline milk-fat interactions
    P Macheras, M Koupparis, S Antimisiaris
    Int. J. Pharm. 54, 123-130 (1989)
    [DOI: 10.1016/0378-5173(89)90331-1] [PDF]
34. A new approach for the invivo evaluation of sustained-release dosage forms
    P Macheras, M Symillides, M Georgiacodis
    Int. J. Pharm. 52, 249-253 (1989)
    [DOI: 10.1016/0378-5173(89)90227-5] [PDF]
35. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept
    PE Macheras, MY Symillides
    Biopharm. Drug Dispos. 10, 43-53 (1989)
    [DOI: 10.1002/bdd.2510100106] [PDF]
36. Pharmacokinetics of acetaminophen after intramuscular administration
    P Macheras, M Parissi-Poulos, L Poulos
    Biopharm. Drug Dispos. 10, 101-105 (1989)
    [DOI: 10.1002/bdd.2510100111] [PDF]
37. Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis
    GN Valsami, PE Macheras, MA Koupparis
    Analyst 114, 387-391 (1989)
    [DOI: 10.1039/an9891400387] [PDF]
38. Effect of temperature and fat-content on the solubility of hydrochlorothiazide and chlorothiazide in milk
    PE Macheras, MA Koupparis, SG Antimisiaris
    J. Pharm. Sci. 78, 933-936 (1989)
    [DOI: 10.1002/jps.2600781111] [PDF]
39. 3-(3-Alkylamino-2-hydroxypropoxy)-derivatives of estratriene. Synthesis and preliminary pharmacological study
    M. Kazanis, P. Macheras, A. Vavayannis
    Chem. Chron. New Ser. 18, 41-46 (1989)
    [PDF]
40. Estimate of volume flow ratio of gastrointestinal (gi) fluids in humans using pharmacokinetic data
    P Macheras, C Reppas, JB Dressman
    Pharm. Res. 7, 518-522 (1990)
    [DOI: 10.1023/A:1015825018361] [PDF]
    Erratum
    P Macheras
    Pharm. Res. 8, 1078-1078 (1991)
    [DOI: 10.1023/A:1015833830347] [PDF]
41. Modified hplc analysis of diltiazem in plasma for pharmacokinetic studies
    M Parissi-Poulou, G Ismailos, P Macheras
    Int. J. Pharm. 62, R13-R16 (1990)
    [DOI: 10.1016/0378-5173(90)90244-X] [PDF]
42. Drug-binding and solubility in milk
    PE Macheras, MA Koupparis, SG Antimisiaris
    Pharm. Res. 7, 537-541 (1990)
    [DOI: 10.1023/A:1015881103340] [PDF]
43. Binding-studies of ions with cyclodextrins using ion-selective electrodes
    GN Valsami, PE Macheras, MA Koupparis
    J. Pharm. Sci. 79, 1087-1094 (1990)
    [DOI: 10.1002/jps.2600791210] [PDF]
44. Development of a computer program for the individualization of theophylline dosage regimens
    P. Macheras, C. Reppas, C. Tsaprounis
    Pneumon 2, 121-126 (1990)
    
45. Binding of drugs in milk - the role of casein in milk protein-binding - comments on the paper by Stebler and Guentert
    P Macheras, C Reppas, S Antimisiaris
    Pharm. Res. 8, 550-550 (1991)
    [DOI: 10.1023/A:1015832118593] [PDF]
46. Evaluation of controlled release formulations - estimation of the duration of the zero-order absorption and ascertainment of absorption kinetics
    P Macheras
    Biopharm. Drug Dispos. 12, 173-187 (1991)
    [DOI: 10.1002/bdd.2510120302] [PDF]
47. Unusual solubility behavior of cyclosporine-a in aqueous-media
    G Ismailos, C Reppas, JB Dressman, P Macheras
    J. Pharm. Pharmacol. 43, 287-289 (1991)
    [DOI: 10.1111/j.2042-7158.1991.tb06688.x] [PDF]
48. Bioavailability study of a freeze-dried sodium phenytoin-milk formulation
    P Macheras, G Ismailos, C Reppas
    Biopharm. Drug Dispos. 12, 687-695 (1991)
    [DOI: 10.1002/bdd.2510120906] [PDF]
49. Binding study of the fluorescence probe 1-anilino-8-naphthalenesulfonate to human plasma and human and bovine serum-albumin using potentiometric titration
    GN Valsami, PE Macheras, MA Koupparis
    Pharm. Res. 8, 888-892 (1991)
    [DOI: 10.1023/A:1015855613083] [PDF]
50. Fraction of the bioavailable dose remaining in the body at the time of peak plasma-concentration in a linear, open, one-compartment model
    P Macheras, C Reppas, M Symillides
    J. Pharm. Sci. 81, 110-112 (1992)
    [DOI: 10.1002/jps.2600810124] [PDF]
51. Equations for the fraction of bioavailable dose remaining in the body in the one-compartment model
    P Macheras, M Symillides, C Reppas
    Biopharm. Drug Dispos. 13, 229-232 (1992)
    [DOI: 10.1002/bdd.2510130309] [PDF]
52. On the assessment of the relative magnitude of rate constants in the linear open one-compartment model
    P Macheras, M Symillides, C Reppas
    J. Pharm. Sci. 81, 1231-1233 (1992)
    [DOI: 10.1002/jps.2600811223] [PDF]
53. Complexation studies of cyclodextrins with tricyclic antidepressants using ion-selective electrodes
    GN Valsami, MA Koupparis, PE Macheras
    Pharm. Res. 9, 94-100 (1992)
    [DOI: 10.1023/A:1018940013006] [PDF]
54. Determination of association constants in cyclodextrin drug complexation using the Scatchard plot - Application to beta-cyclodextrin-anilinonaphthalene sulfonates
    EE Sideris, GN Valsami, MA Koupparis, PE Macheras
    Pharm. Res. 9, 1568-1574 (1992)
    [DOI: 10.1023/A:1015808307322] [PDF]
55. Use of 1-anilino-8-napthalenesulphonate as an ion probe for the potentiometric study of the binding of sulfonamides to bovine serum-albumin and plasma
    A Angelakou, G Valsami, M Koupparis, P Macheras
    J. Pharm. Pharmacol. 45, 434-438 (1993)
    [DOI: 10.1111/j.2042-7158.1993.tb05571.x] [PDF]
56. Estimation of absorption rate-constant in a one-compartment model with the profile of the bioavailable dose eliminated as a function of multiples of half-life
    P Macheras, M Symillides, C Reppas
    J. Pharm. Sci. 82, 1298-1300 (1993)
    [DOI: 10.1002/jps.2600821226] [PDF]
57. Enhancement of cyclosporine-a solubility by d-alphatocopheryl-polyethylene-glycol-1000 succinate (tpgs)
    G Ismailos, C Reppas, P Macheras
    Eur. J. Pharm. Sci. 1, 269-271 (1994)
    [DOI: 10.1016/0928-0987(94)90021-3] [PDF]
58. The Cutoff Time Point of the Partial Area Method for Assessment of Rate of Absorption in Bioequivalence Studies
    P. Macheras, Mira Symillides & Christos Reppas
    Pharm. Res. 11, 831-834 (1994)
    [DOI: 10.1023/A:1018921622981] [PDF]
59. Effect of cyclodextrins on protein-binding of drugs - The diflunisal hydroxypropyl-beta-cyclodextrin model case
    EE Sideris, MA Koupparis, PE Macheras
    Pharm. Res. 11, 90-95 (1994)
    [DOI: 10.1023/A:1018901912619] [PDF]
60. Automated flow-injection serial dynamic dialysis technique in the study of drug-binding with cyclodextrins
    EE Sideris, CA Georgiou, MA Koupparis, PE Macheras
    Anal. Chim. Acta 289, 87-95 (1994)
    [DOI: 10.1016/0003-2670(94)80011-1] [PDF]
61. Automated flow-injection technique for use in dissolution studies of sustained-release formulations - Application to iron(II) formulations
    CA Georgiou, GN Valsami, PE Macheras, MA Koupparis
    J. Pharm. Biomed. Anal. 12, 635-641 (1994)
    [DOI: 10.1016/0731-7085(93)E0015-F] [PDF]
62. General treatment of competitive-binding as applied to the potentiometric ion probe technique - Application to the interaction of nonsteroidal antiinflammatory drugs with bovine serum-albumin
    AT Angelakou, EE Sideris, GN Valsami, MA Koupparis, PE Macheras
    J. Pharm. Sci. 83, 1150-1154 (1994)
    [DOI: 10.1002/jps.2600830816] [PDF]
63. Evaluation of different metrics as indirect measures of rate of drug absorption from extended-release dosage forms at steady-state
    C Reppas, LF Lacey, ON Keene, P Macheras, A Bye
    Pharm. Res. 12, 103-107 (1995)
    [DOI: 10.1023/A:1016246922519] [PDF]
64. Carrier-mediated transport can obey fractal kinetics
    P Macheras
    Pharm. Res. 12, 541-548 (1995)
    [DOI: 10.1023/A:1016201929304] [PDF]
65. Determination of fractal reaction dimension in dissolution studies
    G Valsami, P Macheras
    Eur. J. Pharm. Sci. 3, 163-169 (1995)
    [DOI: 10.1016/0928-0987(95)00005-X] [PDF]
66. Construction of a diflunisal ion sensor and its use in automated flow-injection methods for assay, content uniformity, and dissolution studies of formulations
    P Solich, PE Macheras, MA Koupparis
    J. Pharm. Sci. 84, 889-894 (1995)
    [DOI: 10.1002/jps.2600840720] [PDF]
67. The Geometric Mean Functional Relationship Approach to Linear Regression in Pharmaceutical Studies: Application to the Estimation of Binding Parameters
    Georgia Valsami and Panos Macheras
    Pharm. Sci. 1, 551-554 (1995)
    [DOI: 10.1111/j.2042-7158.1995.tb00377.x] [PDF]
68. A Fractal Approach to Heterogeneous Drug Distribution: Calcium Pharmacokinetics
    P. Macheras
    Pharm. Res. 13, 663-670 (1996)
    [DOI: 10.1023/A:1016031129053] [PDF]
69. Fractal geometry, fractal kinetics and chaos en route to biopharmaceutical sciences
    P. Macheras, Argyrakis, P. & Polymilis
    Eur. J. Drug Metabolism Pharmacokinetics 21, 77-86 (1996)
    [DOI: 10.1007/BF03190255] [PDF]
70. An improved intercept method for the assessment of absorption rate in bioequivalence studies
    P. Macheras, Mira Symillides & Christos Reppas
    Pharm. Res. 13, 1755-1758 (1996)
    [DOI: 10.1023/A:1016421630290] [PDF]
71. Development of a potentiometric kinetic method for drug adsorption studies: The chlorpromazine-charcoal model case
    J Atta-Politou, M Koupparis, P Macheras
    Eur. J. Pharm. Sci. 4, 223-230 (1996)
    [DOI: 10.1016/0928-0987(95)00050-X] [PDF]
72. The effect of polyethylene glycol on the charcoal adsorption of chlorpromazine studied by ion selective electrode potentiometry
    J Atta-Politou, PE Macheras, MA Koupparis
    J. Toxicol.-Clin. Toxicol. 34, 307-316 (1996)
    [DOI: 10.3109/15563659609013795] [PDF]
73. Gastrointestinal Drug Absorption: Is It Time to Consider Heterogeneity as Well as Homogeneity?
    Panos Macheras and Panos Argyrakis
    Pharm. Res. 14, 842-847 (1997)
    [DOI: 10.1023/A:1012183313218] [PDF]
74. A population growth model of dissolution
    A Dokoumetzidis, P Macheras
    Pharm. Res. 14, 1122-1126 (1997)
    [DOI: 10.1023/A:1012182102257] [PDF]
75. Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs
    C Reppas, G Eleftheriou, P Macheras, M Symillides, JB Dressman
    Eur. J. Pharm. Sci. 6, 131-139 (1998)
    [DOI: 10.1016/S0928-0987(97)00077-8] [PDF]
76. Investigation of absorption kinetics by the phase plane method
    A Dokoumetzidis, P Macheras
    Pharm. Res. 15, 1262-1269 (1998)
    [DOI: 10.1023/A:1011952227079] [PDF]
77. The effect of HPMC - a cholesterol-lowering agent - on oral drug absorption in dogs
    C Reppas, G Eleftheriou, P Macheras, M Symillides, D Greenwood, JB Dressman
    Biopharm. Drug Dispos. 19, 523-530 (1998)
    [DOI: 10.1002/(SICI)1099-081X(1998110)19:8<523::AID-BDD133>3.0.CO;2-J] [PDF]
78. An alternative method for the estimation of the terminal slope when a few data points are available
    Aristides Dokoumetzidis, Athanassios Iliadis, and Panos Macheras
    J. Pharm. Sci. 88, 557-560 (1999)
    [DOI: 10.1021/js980317l] [PDF]
79. Heterogeneous tube model for the study of small intestinal transit flow
    A Kalampokis, P Argyrakis, P Macheras
    Pharm. Res. 16, 87-91 (1999)
    [DOI: 10.1023/A:1018874913372] [PDF]
80. Quantitative determination of cefepime in plasma and vitreous fluid by high-performance liquid chromatography
    IN Valassis, M Parissi-Poulou, P Macheras
    J. Chromatogr. B 721, 249-255 (1999)
    [DOI: 10.1016/S0378-4347(98)00468-X] [PDF]
81. Modeling of supersaturated dissolution data
    G Valsami, A Dokoumetzidis, P Macheras
    Int. J. Pharm. 181, 153-157 (1999)
    [DOI: 10.1016/S0378-5173(99)00020-4] [PDF]
82. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts
    A Kalampokis, P Argyrakis, P Macheras
    Pharm. Res. 16, 1764-1769 (1999)
    [DOI: 10.1023/A:1018918402237] [PDF]
83. A displacement approach for competitive drug-protein binding studies using the potentiometric 1-anilino-8-naphthalene-sulfonate probe technique
    A Angelakou, G Valsami, P Macheras, M Koupparis
    Eur. J. Pharm. Sci. 9, 123-130 (1999)
    [DOI: 10.1016/S0928-0987(99)00036-6] [PDF]
84. Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry
    EE Sideris, GN Valsami, MA Koupparis, PE Macheras
    Eur. J. Pharm. Sci. 7, 271-278 (1999)
    [DOI: 10.1016/S0928-0987(98)00035-9] [PDF]
85. On the heterogeneity of drug dissolution and release
    Panos Macheras & Aristides Dokoumetzidis
    Pharm. Res. 17, 108-112 (2000)
    [DOI: 10.1023/A:1007596709657] [PDF]
    Errata: On the heterogeneity of drug dissolution and release. (vol 17, pg 108, 2000)
    P Macheras, A Dokoumetzidis
    Pharm. Res. 18, 719 (2001)
    [DOI: 10.1023/A:1017304632432] [PDF]
86. Non-linear regression analysis with errors in both variables: Estimation of co-operative binding parameters
    G Valsami, A Iliadis, P Macheras
    Biopharm. Drug Dispos. 21, 7-14 (2000)
    [DOI: 10.1002/1099-081X(200001)21:1<7::AID-BDD210>3.0.CO;2-F] [PDF]
87. Cyclosporin a pharmacokinetics in liver transplant recipients effect of ursodeoxycholic acid.
    A Iliadis, P Macheras, FX Caroli-Bosc, AM Montet, L Salmon, JC Montet
    Gastroenterology 118, A984-A984 (2000)
    [DOI: 10.1016/S0016-5085(00)86082-5] [PDF]
88. On the use of partial AUC as an early exposure metric
    A Dokoumetzidis, P Macheras
    Eur. J. Pharm. Sci. 10, 91-95 (2000)
    [DOI: 10.1016/S0928-0987(99)00095-0] [PDF]
89. Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients
    FX Caroli-Bose, A Iliadis, L Salmon, P Macheras, AM Montet, A Bourgeon, R Garraffo, JP Delmont, JC Montet
    Fundam. Clin. Pharmacol. 14, 601-609 (2000)
    [DOI: 10.1111/j.1472-8206.2000.tb00446.x] [PDF]
90. Nonlinear Dynamics and Chaos Theory: Concepts and Applications Relevant to Pharmacodynamics
    Aristides Dokoumetzidis, Athanassios Iliadis, and Panos Macheras
    Pharm. Res. 18, 415-426 (2001)
    [DOI: 10.1023/A:1011083723190] [PDF]
91. A Stochastic Model Describes the Heterogeneous Pharmacokinetics of Cyclosporin
    Laurent Claret, Athanassios Iliadis, and Panos Macheras
    J. Pharmacokinet. Pharmacodyn. 28, 445-463 (2001)
    [DOI: 10.1023/A:1012295014352] [PDF]
92. Fractal volume of drug distribution: It scales proportionally to body mass
    V Karalis, L Claret, A Iliadis, P Macheras
    Pharm. Res. 18, 1056-1060 (2001)
    [DOI: 10.1023/A:1010965001162] [PDF]
93. Drug disposition viewed in terms of the fractal volume of distribution
    V Karalis, P Macheras
    Pharm. Res. 19, 697-704 (2002)
    [DOI: 10.1023/A:1015378701592] [PDF]
94. Multivariate Statistics of Disposition Pharmacokinetic Parameters for Structurally Unrelated Drugs Used in Therapeutics
    Vangelis Karalis, Anna Tsantili-Kakoulidou, and Panos Macheras
    Pharm. Res. 19, 1827-1834 (2002)
    [DOI: 10.1023/A:1021489323828] [PDF]
95. Nonlinear dynamics in Clinical Pharmacology: the paradigm of cortisol secretion and suppression
    A Dokoumetzidis, A Iliadis, P Macheras
    Br. J. Clin. Pharmacol. 54, 21-29 (2002)
    [DOI: 10.1046/j.1365-2125.2002.01600.x] [PDF]
96. In silico prediction of ADME and pharmacokinetics - Report of an expert meeting organised by COST B15
    A Boobis, U Gundert-Remy, P Kremers, P Macheras, O Pelkonen
    Eur. J. Pharm. Sci. 17, 183-193 (2002)
    [DOI: 10.1016/S0928-0987(02)00185-9] [PDF]
97. Fractal kinetics in drug release from finite fractal matrices
    K. Kosmidis, P. Argyrakis and P. Macheras
    J. Chem. Phys. 119, 6373-7377 (2003)
    [DOI: 10.1063/1.1603731] [PDF]
98. The mean dissolution time depends on the dose/solubility ratio
    E Rinaki, A Dokoumetzidis, P Macheras
    Pharm. Res. 20, 406-408 (2003)
    [DOI: 10.1023/A:1022652004114] [PDF]
99. A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function
    Kosmas Kosmidis, Panos Argyrakis, and Panos Macheras
    Pharm. Res. 20, 988-995 (2003)
    [DOI: 10.1023/A:1024497920145] [PDF]
100. Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
     Eleni Rinaki, Georgia Valsami, and Panos Macheras
     Pharm. Res. 20, 1917-1925 (2003)
     [DOI: 10.1023/B:PHAM.0000008037.57884.11] [PDF]
101. The power law can describe the 'entire' drug release curvefrom HPMC-based matrix tablets: a hypothesis
     E. Rinaki, G. Valsami, P. Macheras
     Int. J. Pharm. 255, 199-207 (2003)
     [DOI: 10.1016/S0378-5173(03)00079-6] [PDF]
102. A model for transport and dispersion in the circulatory system based on the vascular fractal tree
     A Dokoumetzidis, P Macheras
     Ann. Biomed. Eng. 31, 284-293 (2003)
     [DOI: 10.1114/1.1555627] [PDF]
103. Analysis of Case II drug transport with radial and axial release from cylinders
     K Kosmidis, E Rinaki, P Argyrakis, P Macheras
     Int. J. Pharm. 254, 183-188 (2003)
     [DOI: 10.1016/S0378-5173(03)00030-9] [PDF]
104. Pharmacodynamic considerations in bioequivalence assessment: comparison of novel and existing metrics
     V Karalis, P Macheras
     Eur. J. Pharm. Sci. 19, 45-56 (2003)
     [DOI: 10.1016/S0928-0987(03)00064-2] [PDF]
105. Quantitative structure-pharmacokinetic relationships for disposition parameters of cephalosporins
     V Karalis, A Tsantili-Kakoulidou, P Macheras
     Eur. J. Pharm. Sci. 20, 115-123 (2003)
     [DOI: 10.1016/S0928-0987(03)00177-5] [PDF]
106. Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles
     Honghui Zhou
     J. Clin. Pharmacol. 43, 211-227 (2003)
     [DOI: 10.1177/0091270002250613] [PDF]
107. Population pharmacokinetic/pharmacodynamic methods and their application Population pharmacokinetic/pharmacodynamic methods and their application: an introduction
     P. Macheras, J. Lukas.
     Pharmakeftiki 16, 65-68, (2003)
     
108. Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples
     Eleni Rinaki, Aristides Dokoumetzidis, Georgia Valsami, and Panos Macheras
     Pharm. Res. 21, 1567-1572 (2004)
     [DOI: 10.1023/B:PHAM.0000041450.25106.c8] [PDF]
109. A physiologically based approach for the estimation of recirculatory parameters
     V Karalis, A Dokoumetzidis, P Macheras
     J. Pharmacol. Exp. Ther. 308, 198-205 (2004)
     [DOI: 10.1124/jpet.103.058941] [PDF]
110. The heterogenous course of drug transit through the body
     A Dokoumetzidis, V Karalis, A Iliadis, P Macheras
     Trends Pharmacol. Sci. 25, 140-146 (2004)
     [DOI: 10.1016/j.tips.2004.01.008] [PDF]
111. Michaelis-Menten kinetics under spatially constrained conditions: Application to mibefradil pharmacokinetics
     K Kosmidis, V Karalis, P Argyrakis, P Macheras
     Biophys. J. 87, 1498-1506 (2004)
     [DOI: 10.1529/biophysj.104.042143] [PDF]
112. Novel scaled average bioequivalence limits based on GMR and variability considerations
     V Karalis, M Symillides, P Macheras
     Pharm. Res. 21, 1933-1942 (2004)
     [DOI: 10.1023/B:PHAM.0000045249.83899.ae] [PDF]
113. Pharmacokinetics of teicoplanin in an ICU population of children and infants
     JC Lukas, G Karikas, M Gazouli, P Kalabalikis, T Hatzis, P Macheras
     Pharm. Res. 21, 2064-2071 (2004)
     [DOI: 10.1023/B:PHAM.0000048198.56873.d8] [PDF]
114. Modeling and Monte Carlo simulations in oral drug absorption
     A Dokoumetzidis, K Kosmidis, P Argyrakis, P Macheras
     Basic Clin. Pharmacol. Toxicol. 96, 200-205 (2005)
     [DOI: 10.1111/j.1742-7843.2005.pto960309.x] [PDF]
115. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties
     V Karalis, P Macheras, M Symillides
     Eur. J. Pharm. Sci. 26, 54-61 (2005)
     [DOI: 10.1016/j.ejps.2005.04.019] [PDF]
116. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates
     G Inclan, E Suarez, R Calvo, C Aguirre, P Macheras, M Gazouli, JC Lukas
     Int. J. Antimicrob. Agents 26, 304-311 (2005)
     [DOI: 10.1016/j.ijantimicag.2005.05.004] [PDF]
117. Analysis of Dissolution Data Using Modified Versions of Noyes-Whitney Equation and the Weibull Function
     Aristides Dokoumetzidis, Vasiliki Papadopoulou & Panos Macheras
     Pharm. Res. 23, 256-261 (2006)
     [DOI: 10.1007/s11095-006-9093-3] [PDF]
118. On the use of the Weibull function for the discernment of drug release mechanisms
     Vasiliki Papadopoulou, Kosmas Kosmidis, Marilena Vlachou, Panos Macheras
     Int. J. Pharm. 309, 44-50 (2006)
     [DOI: 10.1016/j.ijpharm.2005.10.044] [PDF]
119. A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System
     Aristides Dokoumetzidis, Panos Macheras
     Int. J. Pharm. 321, 1-11 (2006)
     [DOI: 10.1016/j.ijpharm.2006.07.011] [PDF]
120. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique
     A. Davilas, M. Koupparis, P. Macheras, G. Valsami
     J. Pharm. Pharmacol. 58, 1467-1474 (2006)
     [DOI: 10.1211/jpp.58.11.0007] [PDF]
121. A comment on "adverse drug reactions and avalanches: Life at the edge of chaos"
     Aristides Dokoumetzidis, Panos Macheras
     J. Clin. Pharmacol. 46, 1057-1058 (2006)
     [DOI: 10.1177/0091270006291620] [PDF]
122. Novel scaled bioequivalence limits with leveling-off properties
     John Kytariolos, Vangelis Karalis, Panos Macheras, Mira Symillides
     Pharm. Res. 23, 2657-2664 (2006)
     [DOI: 10.1007/s11095-006-9107-1] [PDF]
123. Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts
     K. Sandy Pang, Michael Weiss, and Panos Macheras
     APPS J. 9, E268-E283 (2007)
     [DOI: 10.1208/aapsj0902030] [PDF]
124. Modelling and simulation in drug absorption processes
     A. Dokoumetzidis, G. Valsami, P. Macheras
     Xenobiotica 37, 1052-1065 (2007)
     [DOI: 10.1080/00498250701502114] [PDF]
125. Monte Carlo simulations for the study of drug release from matrices with high and low diffusivity areas
     Kosmas Kosmidis, Panos Macheras
     Int. J. Pharm. 343, 166-172 (2007)
     [DOI: 10.1016/j.ijpharm.2007.05.021] [PDF]
126. IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure
     A. Dokoumetzidis, P. Macheras
     J. Control. Release 129, 76-78 (2008)
     [DOI: 10.1016/j.jconrel.2008.04.005] [PDF]
127. Monte Carlo simulations of drug release from matrices with periodic layers of high and low diffusivity
     Kosmas Kosmidis, Panos Macheras
     Int. J. Pharm. 354, 111-116 (2008)
     [DOI: 10.1016/j.ijpharm.2007.10.036] [PDF]
128. Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments
     A. Dokoumetzidis, V. Papadopoulou, G. Valsami, P. Macheras
     Int. J. Pharm. 355, 114-125 (2008)
     [DOI: 10.1016/j.ijpharm.2007.11.056] [PDF]
129. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples
     Vasiliki Papadopoulou, Georgia Valsami, Aristides Dokoumetzidis, Panos Macheras
     Int. J. Pharm. 361, 70-77 (2008)
     [DOI: 10.1016/j.ijpharm.2008.05.021] [PDF]
130. Bioavailability and Bioequivalence: Focus on physiological factors and variability
     Vangelis Karalis, Panos Macheras, Achiel Van Peer, Vinod P. Shah
     Pharm. Res. 25, 1956-1962 (2008)
     [DOI: 10.1007/s11095-008-9645-9] [PDF]
131. Fractional kinetics in drug absorption and disposition processes
     Aristides Dokoumetzidis and Panos Macheras
     J. Pharmacokinet. Pharmacodyn. 36, 165-178 (2009)
     [DOI: 10.1007/s10928-009-9116-x] [PDF]
132. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: Focus on human exposure to drugs
     Vangelis Karalis, Mira Symillides, Panos Macheras
     Eur. J. Pharm. Sci. 38, 55-63 (2009)
     [DOI: 10.1016/j.ejps.2009.05.013] [PDF]
133. Physiologically-Based PK/PD Modelling of Therapeutic Macromolecules
     Peter Thygesen, Panos Macheras, Achiel Van Peer
     Pharm. Res. 26, 2543-2550 (2009)
     [DOI: 10.1007/s11095-009-9990-3] [PDF]
134. Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of Praziquantel
     Stratos Maragos, Helen Archontaki, Panos Macheras, Georgia Valsami
     AAPS PharmSciTech 10, 1444-1451 (2009)
     [DOI: 10.1208/s12249-009-9346-7] [PDF]
135. Pharmacogenetics in individualized therapy for brain cancer patients
     E. Magklara, I. Vizirianakis, P. Macheras.
     Pharmakeftiki 22, 117-123 (2009)
     
136. Novel milk-based oral formulations: Proof of concept
     Georgia Charkoftaki, John Kytariolos, Panos Macheras
     Int. J. Pharm. 390, 150-159 (2010)
     [DOI: 10.1016/j.ijpharm.2010.001.038] [PDF]
137. A commentary on fractionalization of multi-compartmental models
     Aristides Dokoumetzidis, Richard Magin, Panos Macheras
     J. Pharmacokinet. Pharmacodyn. 37, 203-207 (2010)
     [DOI: 10.1007/s10928-010-9153-5] [PDF]
138. Fractional kinetics in multi-compartmental systems
     Aristides Dokoumetzidis, Richard Magin, Panos Macheras
     J. Pharmacokinet. Pharmacodyn. 37, 507-524 (2010)
     [DOI: 10.1007/s10928-010-9170-4] [PDF]
139. Examining the Role of Metabolites in Bioequivalence Assessment
     Vangelis Karalis, Panos Macheras
     J. Pharm. Pharmaceut. Sci. 13, 198-217 (2010)
     [DOI: 10.18433/J35889] [PDF]
140. Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations
     Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
     Basic Clin. Pharmacol. Toxicol. 106, 168-172 (2010)
     [DOI: 10.1111/j.1742-7843.2009.00506.x] [PDF]
141. Power law IVIVC: An application of fractional kinetics for drug release and absorption
     John Kytariolos, Aristides Dokoumetzidis, Panos Macheras
     Eur. J. Pharm. Sci. 41, 299-304 (2010)
     [DOI: 10.1016/j.ejps.2010.06.015] [PDF]
142. From drug delivery systems to drug release, dissolution IVIVC, BCS, BDDCS, bioequivalence and biowaivers
     V. Karalis, E. Magklara, V. Shah, P. Macheras
     Pharmaceutical Research. 27, 2018-2029 (2010)
     
143. Computational-Regulatory Developments in the Prediction of Oral Drug Absorption
     G. Valsami, P. Macheras
     Mol. Inf. 30, 112-121 (2011)
     [DOI: 10.1002/minf.201000171] [PDF]
144. Novel methods to assess bioequivalence
     Vangelis Karalis, Mira Symillides, Panos Macheras
     Expert Opin. Drug Metab. Toxicol. 7, 79-88 (2011)
     [DOI: 10.1517/17425255.2011.539202] [PDF]
145. Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case
     Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
     J. Pharm. Pharmacol. 63, 352-361 (2011)
     [DOI: 10.1111/j.2042-7158.2010.01226.x] [PDF]
146. The Changing Face of the Rate Concept in Biopharmaceutical Sciences: From Classical to Fractal and Finally to Fractional
     Aristides Dokoumetzidis, Panos Macheras
     Pharm. Res. 28, 1229-1232 (2011)
     [DOI: 10.1007/s11095-011-0370-4] [PDF]
147. From the Higuchi Law and the linear ivivc to fractional kinetics and the nonlinear ivivc
     Aristides Dokoumetzidis, Panos Macheras
     Eur. J. Pharm. Sci. 44, Supplement 1, 17 (2011) [Proceedings of "4th BBBB International Conference on Pharmaceutical Sciences"]
     [Source: ScienceDirect]
148. Monte Carlo simulations and fractional kinetics considerations for the Higuchi equation
     Aristides Dokoumetzidis, Kosmas Kosmidis, Panos Macheras
     Int. J. Pharm. 418, 100-103 (2011)
     [DOI: 10.1016/j.ijpharm.2010.11.046] [PDF]
149. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline
     Vangelis Karalis, Mira Symillides, Panos Macheras
     Eur. J. Pharm. Sci. 44, 497-505 (2011)
     [DOI: 10.1016/j.ejps.2011.09.008] [PDF]
150. From Supersaturated Drug Delivery Systems to the Rising Era of Pediatric Formulations
     G. Charkoftaki, G. Valsami, P. Macheras
     Chem. Biochem. Eng. Q. 26, 427-434 (2012)
     [DOI: 10.15255/CABEQ.2014.119]
151. Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA
     Vangelis Karalis, Mira Symillides, Panos Macheras
     Pharm. Res. 29, 1066-1077 (2012)
     [DOI: 10.1007/s11095-011-0651-y] [PDF]
152. Current regulatory approaches of bioequivalence testing
     Vangelis Karalis, Panos Macheras
     Expert Opin. Drug Metab. Toxicol. 8, 929-942 (2012)
     [DOI: 10.1517/17425255.2012.690394] [PDF]
153. Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS
     Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
     Pharm. Res. 29, 3188-3198 (2012)
     [DOI: 10.1007/s11095-012-0815-4] [PDF]
154. Medication for the treatment of lung cancer: Emphasis on aerosolized chemotherapy
     K. Soulele, E. Christodoulou, P. Macheras.
     Pneumon 25, 298-304 (2012)
     
155. Stability and physicochemical characterization of novel milk-based oral formulations
     J. Kytariolos, G. Charkoftaki, J. R. Smith, G. Voyiatzis, A. Chrissanthopoulos, S. N. Yannopoulos, D. G. Fatouros, P. Macheras
     Int. J. Pharm. 444, 128-138 (2013)
     [DOI: 10.1016/j.ijpharm.2013.01.022] [PDF]
156. Exploring the Relationships Between Scaled Bioequivalence Limits and Within-Subject Variability
     Mira Symillides, Vangelis Karalis, Panos Macheras
     J. Pharm. Sci. 102, 297-301 (2013)
     [DOI: 10.1002/jps.23365] [PDF]
157. An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies
     Vangelis Karalis, Panos Macheras
     Pharm. Res. 30, 1824-1835 (2013)
     [DOI: 10.1007/s11095-013-1026-3] [PDF]
158. Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review
     Panos Macheras, Vangelis Karalis, Georgia Valsami
     J. Pharm. Sci. 102, 3018-3036 (2013)
     [DOI: 10.1002/jps.23534] [PDF]
159. A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms
     Anne Zajicek, Michael J. Fossler, Jeffrey S. Barrett, Jeffrey H. Worthington, Robert Ternik, Georgia Charkoftaki, Susan Lum, Joerg Breitkreutz, Mike Baltezor, Panos Macheras, Mansoor Khan, Shreeram Agharkar, David Douglas MacLaren
     AAPS J. 15, 1072-1081 (2013)
     [DOI: 10.1208/s12248-013-9511-5] [PDF]
160. On the ubiquitous presence of fractals and fractal concepts in pharmaceutical sciences: A review
     Natassa Pippa, Aristides Dokoumetzidis, Costas Demetzos, Panos Macheras
     Int. J. Pharm. 456, 340-352 (2013)
     [DOI: 10.1016/j.ijpharm.2013.08.087] [PDF]
161. Quantitative assessment of the switchability of generic products
     Vangelis Karalis, Meir Bialer, Panos Macheras
     Eur. J. Pharm. Sci. 50, 476-483 (2013)
     [DOI: 10.1016/j.ejps.2013.08.023] [PDF]
162. A non-binary biopharmaceutical classification of drugs: The ABΓ system
     Panos Macheras, Vangelis Karalis
     Int. J. Pharm. 464, 85-90 (2014)
     [DOI: 10.1016/j.ijpharm.2014.01.022] [PDF]
163. On the statistical model of the two-stage designs in bioequivalence assessment
     Vangelis Karalis, Panos Macheras
     J. Pharm. Pharmacol. 66, 48-52 (2014)
     [DOI: 10.1111/jphp.12164] [PDF]
164. Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations
     Vangelis Karalis, Panos Macheras, Meir Bialer
     CNS Drugs 28, 69-77 (2014)
     [DOI: 10.1007/s40263-013-0112-8] [PDF]
165. Comment and reply on: A randomized crossover trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma of chronic obstructive pulmonary disease
     Panos Macheras
     Expert Opin. Drug Deliv. 11, 823-824 (2014)
     [DOI: 10.1517/17425247.2014.889648] [PDF]
166. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers
     K. Soulele, P. Macheras, L. Silvestro, S. Rizea Savu, V. Karalis
     Eur. J. Pharm. Sci. 80, 33-42 (2015)
     [DOI: 10.1016/j.ejps.2015.08.009] [PDF]
167. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence
     Chrysa Daousani, Panos Macheras
     Int. J. Pharm. 478, 606-609 (2015)
     [DOI: 10.1016/j.ijpharm.2014.11.062] [PDF]
168. Milk as a medium for pediatric formulations: Experimental findings and regulatory aspects
     Konstantina Soulele, Panos Macheras
     Int. J. Pharm. 492, 344-345 (2015)
     [DOI: 10.1016/j.ijpharm.2015.05.015] [PDF]
169. Biopharmaceutic classification of drugs revisited
     Chrysa Daousani, Panos Macheras
     Eur. J. Pharm. Sci. 95, 82-87 (2016)
     [DOI: 10.1016/j.ejps.2016.08.001] [PDF]
170. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers
     Konstantina Soulele, Panos Macheras, Vangelis Karalis
     Biopharm. Drug Disp. 38, 407-419 (2017)
     [DOI: 10.1002/bdd.2077] [PDF]
171. Modeling and administration scheduling of fractional-order pharmacokinetic systems
     Domagoj Herceg, Sotiris Ntouskas, Pantelis Sopasakis, Aris Dokoumetzidis, Panos Macheras, Haralambos Sarimveis, Panagiotis Patrinos
     IFAC PAPERSONLINE 50, 9742-9747 (2017)
     [DOI: 10.1016/j.ifacol.2017.08.2178] [PDF]
172. On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches
     K. Soulele, P. Macheras, V. Karalis
     Pulmonary Pharmacology and Therauptics 48, 168-178 (2018)
     [DOI: 10.1016/j.pupt.2017.12.002] [PDF]
173. On the dilemma of fractal or fractional kinetics in drug release studies: A comparison between Weibull and Mittag-Leffler functions
     Kosmas Kosmidis, Panos Macheras
     Int. J. Pharm. 543, 269-273 (2018)
     [DOI: 10.1016/j.ijpharm.2018.03.060] [PDF]
174. Fractional calculus in pharmacokinetics
     Pantelis Sopasakis, Haralambos Sarimveis, Panos Macheras, Aristides Dokoumetzidis
     J. Pharmacokinet. Pharmacodyn. 45, 107-125 (2018)
     [DOI: 10.1007/s10928-017-9547-8] [PDF]
175. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs
     Panos Macheras, Athanassios Iliadis, Georgia Melagraki
     Eur. J. Pharm. Sci. 117, 98-106 (2018)
     [DOI: 10.1016/j.ejps.2018.02.003] [PDF]
176. On the unphysical hypotheses in pharmacokinetics and oral drug absorption: Time to utilize instantaneous rate coefficients instead of rate constants
     Panteleimon D. Mavroudis, Kosmas Kosmidis, Panos Macheras
     Eur. J. Pharm. Sci. 130, 137-146 (2019)
     [DOI: 10.1016/j.ejps.2019.01.027] [PDF]
177. On an Unphysical Hypothesis of Bateman Equation and its Implications for Pharmacokinetics
     Panos Macheras
     Pharm. Res. 36, 94 (2019)
     [DOI: 10.1007/s11095-019-2633-4] [PDF]
178. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS)_ Beyond guidelines
     Aggelos Charalabidis, Maria Sfouni, Christel Bergström, Panos Macheras
     Int. J. Pharm. 566, 264-281 (2019)
     [DOI: 10.1016/j.ijpharm.2019.05.041] [PDF]
179. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts
     Panos Macheras, Pavlos Chryssafidis
     Pharm. Res. 37, 187 (2020)
     [DOI: 10.1007/s11095-020-02894-w] [PDF]
     Correction to: Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts
     Panos Macheras, Pavlos Chryssafidis
     Pharm. Res. 37, 206 (2020)
     [DOI: 10.1007/s11095-020-02935-4] [PDF]
180. A fractal kinetics SI model can explain the dynamics of COVID-19 epidemics
     Kosmas Kosmidis, Panos Macheras
     PLOS One 15, e0237304 (2020)
     [DOI: 10.1371/journal.pone.0237304] [PDF]
181. Demystifying the spreading of pandemics I: The fractal kinetics SI model quantifies the dynamics of COVID-19
     Panos Macheras, Kosmas Kosmidis, Pavlos Chryssafidis
     meRxiv (2020)
     [DOI: 10.1101/2020.11.15.20232132] [PDF]
182. Interpreting airborne pandemics spreading using fractal kinetics' principles
     P. Macheras, A. A. Tsekouras, and P. Chryssafidis
     F1000Research 10, 609 (2021)
     [DOI: 10.12688/f1000research.53196.1] [PDF]
183. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations
     Pavlos Chryssafidis, Athanasios A. Tsekouras, Panos Macheras
     Pharm. Res. 38, 1345-1356 (2021)
     [DOI: 10.1007/s11095-021-03078-w] [PDF]
     Correction to: Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations
     Pavlos Chryssafidis, Athanasios A. Tsekouras, Panos Macheras
     Pharm. Res. 38, 1633 (2021)
     [DOI: 10.1007/s11095-021-03101-0] [PDF]
184. Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation
     K. Soulele, T. Karampelas, C. Tamvakopoulos, P. Macheras
     Pharm. Res. 38, 1419-1428 (2021)
     [DOI: 10.1007/s11095-021-03085-x] [PDF]
185. Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts
     Athanasios A. Tsekouras, Panos Macheras
     Pharm. Res. 38, 1635-1638 (2021)
     [DOI: 10.1007/s11095-021-03121-w] [PDF]
     Correction to: Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts
     Athanasios A. Tsekouras, Panos Macheras
     Pharm. Res. 38, 2185 (2021)
     [DOI: 10.1007/s11095-021-03148-z] [PDF]
186. Drugs are Absorbed in Finite Time: A New Era in Biopharmaceutics and Pharmacokinetics
     P. Macheras
     Acta Pharmaceutica Hungarica. 85, 148-149 (2021)
     [DOI: 10.33892/aph.2021.91.148-149]
187. Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models
     P. Chryssafidis, A. A. Tsekouras, P. Macheras
     Pharm. Res. 39, 691-701 (2022)
     [DOI: 10.1007/s11095-022-03230-0] [PDF]
188. From Camille Nούς to Apollonian and the Dionysian scientists
     Panos Macheras, Caitlin Di Paolo, Yanna Pusica and Eleftherios P. Diamandis
     Diagnosis 9, 1-2 (2022)
     [DOI: 10.1515/dx-2021-0057] [PDF]
189. Columbus' egg: Oral drugs are absorbed in finite time
     P. Macheras, A. A. Tsekouras
     Eur. J. Pharm. Sci. 176, 106265 (2022)
     [DOI: 10.1016/j.ejps.2022.106265] [PDF] [Supplementary Information]
190. Physiologically based pharmacokinetic models under the prism of the finite absorption time concept
     Di Wu, Athanasios A. Tsekouras, Panos Macheras, Filippos Kesisoglou
     Pharm. Res. 40, 419-429 (2023)
     [DOI: 10.1007/s11095-022-03357-0] [PDF]
191. The Finite Absorption Time (FAT) Concept en route to PBPK modeling and pharmacometrics
     Athanasios A. Tsekouras, Panos Macheras
     J. Pharmacokin. Pharmacodyn. 50, 5-10 (2023)
     [DOI: 10.1007/s10928-022-09832-w] [PDF]
192. Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept
     Athanasios A. Tsekouras, Panos Macheras
     Eur. J. Drug Metabol. Pharmacokin. 48, 455-462 (2023)
     [DOI: 10.1007/s13318-023-00831-x] [PDF]
193. Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption
     N. Alimpertis, A. A. Tsekouras, P. Macheras
     Pharm. Res. 40, 2167-2175 (2023)
     [DOI: 10.1007/s11095-023-03578-x] [PDF] [Supplementary Information]
194. IVIVC revised
     N. Alimpertis, A. Simitopoulos, A. A. Tsekouras, P. Macheras
     Pharm. Res. 41, 235-246 (2024)
     [DOI: 10.1007/s11095-024-03653-x] [PDF]
195. Coupling Drug Dissolution with BCS
     A. Simitopoulos, A. A. Tsekouras, P. Macheras
     Pharm. Res. 41, 481-491 (2024)
     [DOI: 10.1007/s11095-024-03661-x] [PDF]
196. Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence
     A. A. Tsekouras, P. Macheras
     Pharm. Res. 41, 1412-1425 (2024)
     [DOI: 10.1007/s11095-024-03727-w] [PDF]
197. FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes
     E. Toulitsis, A. A. Tsekouras, P. Macheras
     Pharmaceutics 16, 1435 (2024)
     [DOI: 10.3390/pharmaceutics16111435] [PDF] [Supplementary Information]

• The solution of a system of differential equations occurring in the theory of radio-active transformations
  H. Bateman
  Proc. Cambridge Philos. Soc. Math. Phys. Sci. 15, 423-427 (1910)
  [DOI: https://www.biodiversitylibrary.org/item/97262#page/487/mode/1up] or [https://archive.org/details/cbarchive_122715_solutionofasystemofdifferentia1843] [PDF]
• The absorption of adrenalin
  D. Murray Lyon
  J. Exp. Med. 38, 655-665 (1923)
  [DOI: 10.1084/jem.38.6.655] [PDF]
• Harry Bateman 1882-1946
  F. D. Murnaghan
  Bull. Am. Math. Soc. 54, 88-103 (1948)
  [DOI: https://doi.org/10.1090/S0002-9904-1948-08955-8] [PDF]
• Blood Quinidine Concentrations as a Guide in the Treatment of Cardiac Arrhythmias
  Maurice Sokolow, and A. L. Edgar
  Circulation 1, 576-592 (1950)
  [DOI: 10.1161/01.CIR.1.4.576] [PDF]
• Per cent absorbed time plots derived from blood level and/or urinary excretion data
  J. G. Wagner, E. Nelson
  J. Pharm. Sci. 52, 610-611 (1963)
  [DOI: 10.1002/jps.2600520629] [PDF]
• Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug
  John G. Wagner, Eino Nelson
  J. Pharm. Sci. 53, 1392-1403 (1964)
  [DOI: 10.1002/jps.2600531126] [PDF]
• New method for calculating the intrinsic absorption rate of drugs
  J. C. Loo, S. Riegelman
  J. Pharm. Sci. 57, 918-928 (1968)
  [DOI: 10.1002/jps.2600570602] [PDF]
• An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects
  A. J. Glazko, A. W. Kinkel, W. C. Alegnani, E. L. Holmes
  Clin. Pharmacol. Therap. 9, 472-483 (1968)
  [DOI: 10.1002/cpt196894472] [PDF]
• Brand, Generic Drugs Differ In Man; Absorption Rates Vary
  C. M. Martin, M. Rubin, W. E. O'Malley, V. F. Garagusi, C. E. McCauley
  JAMA 205, (9) 23-24, 30 (1968)
  [DOI: 10.1001/jama.1968.03140350005003] [PDF]
• Kinetics and absolute bioavailability of atenolol
  William D. Mason, Nathaniel Winer, Gregory Kochak, Irving Cohen, Robert Bell
  Clin. Pharmacol. Therap. 25, 408-415 (1979)
  [DOI: 10.1002/cpt1979254408] [PDF]
• Outbreak of Anticonvulsant Intoxication in an Australian City
  J. H. Tyrer, M. J. Eadie, J. M. Sutherland, W. D. Hooper
  Br. Med. J. 4, 271-273 (1970)
  [DOI: 10.1136/bmj.4.5730.271] [PDF]
• Bioavailability of Digoxin
  Trieste G. Vitti, Daniel Banes, Theodore E. Byers
  New Engl. J. Med. 285, 1433-1434 (1971)
  [DOI: 10.1056/nejm197112162852512] [PDF]
• Bioavailability of digoxin
  E. J. Fraser, R. H. Leach, J. W. Poston
  Lancet 300, 541-541 (1972)
  [DOI: 10.1016/S0140-6736(72)91936-8] [PDF]
• Comparative bioavailability of three brands of ampicillin
  C. MacLeod, H. Rabin, J. Ruedy, M. Caron, D. Zarowny, and R. O. Davies
  Can. Med. Ass. J. 107, 203-209 (1972)
  [DOI: www.cmaj.ca/content/107/3/203] [PDF]
• Pharmacokinetics of Digoxin: Interpreting Bioavailability
  N. Sanchez, L. B. Sheiner, H. Halkin, K. L. Melmon
  Br. Med. J. 4, 132-134 (1973)
  [DOI: 10.1136/bmj.4.5885.132] [PDF]
• Equivalence Lack in Digoxin Plasma Levels
  John G. Wagner, Marianne Christensen, Ermelinda Sakmar, Donald Blair, James D. Yates, Park W. Willis III, Allen J. Sedman, Roger G. Stoll
  J. Amer. Med. Ass. 224, 199-204 (1973)
  [DOI: 10.1001/jama.1973.03220150013004] [PDF]
• Comparative Bioavailabilities from Truncated Blood Level Curves
  E. G. Lovering, I.J. McGilveray, I. McMillan, W. Tostowaryk
  J. Pharm. Sci. 64, 1521-1524 (1975)
  [DOI: 10.1002/jps.2600640921] [PDF]
• Influence of diet and fluid on bioavailability of theophylline
  P. G. Welling, L. L. Lyons, W. A. Craig, G. A. Trochta
  Clin. Pharmacol. Therap. 17, 475-480 (1975)
  [DOI: 10.1002/cpt1975174475] [PDF]
• Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action
  S. H. Ngai, Barry A. Berkowitz, J. C. Yang, James Hempstead, Sydney Spector
  Anesthesiology 44, 398-401 (1976)
  [DOI: 10.1097/00000542-197605000-00008] [PDF]
• Rapid method of obtaining area under curve for any compartment of any linear pharmacokinetic model in terms of rate constants
  John G. Wagner
  J. Pharmacokin. Biopharmac. 4, 281-285 (1976)
  [DOI: 10.1007/BF01063618] [PDF]
• A completely absorbed oral preparation of digoxin
  B. F. Johnson, Carole Bye, Glynne Jones, and G. A. Sabey
  Clin. Pharmacol. Therap. 16, 746-751 (1976)
  [DOI: 10.1002/cpt1976196746] [PDF]
• Bioavailability assessment: Methods to estimate total area (AUC 0-∞) and total amount excreted (A_e^∞) and importance of blood and urine sampling scheme with application to digoxin
  John G. Wagner and James W. Ayres
  J. Pharmacokin. Biopharmac. 5, 533-557 (1977)
  [DOI: 10.1007/BF01061733] [PDF]
• Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man
  J. W. Ayres, D. J. Weidler, J. MacKichan, E. Sakmar, M. R. Hallmark, E. F. Lemanowicz & J. G. Wagner
  Europ. J. Clin. Pharmacol. 12, 421-428 (1977)
  [DOI: 10.1007/BF00561061] [PDF]
• Absolute Bioavailability of Oral Theophylline
  Leslie Hendeles, Miles Weinberger and Lyle Bighley
  Am. J. Hosp. Pharm. 34, 525-527 (1977)
  [DOI: 10.1093/ajhp/34.5.525] [PDF]
• Use of area under the curve to estimate absolute bioavailability of digoxin
  W. G. Kramer, R. H. Reuning
  J. Pharm. Sci. 67, 141-142 (1978)
  [DOI: 10.1002/jps.2600670145] [PDF]
• Flucytosine kinetics in subjects with normal and impaired renal function
  Ralph E. Cutler, Andrew D. Blair, Michael R. Kelly
  Clin. Pharmacol. Therap. 24, 333-342 (1978)
  [DOI: 10.1002/cpt1978243333] [PDF]
• Numerical deconvolution by least squares: use of prescribed input functions
  David J. Cutler
  J. Pharmacokin. Biopharm. 6, 227-241 (1978)
  [DOI: 10.1007/BF01312264] [PDF]
• Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
  Win L. Chiou
  J. Pharmacokin. Biopharm. 6, 539-546 (1978)
  [DOI: 10.1007/BF01062108] [PDF]
• Statistical moments in pharmacokinetics
  Kiyoshi Yamaoka, Terumichi Nakagawa & Toyozo Uno
  J. Pharmacokin. Biopharm. 6, 547-558 (1978)
  [DOI: 10.1007/BF01062109] [PDF]
• Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: Increasing the power of bioavailability tests
  Henry d'A. Heck, Sidney E. Buttrill, Jr., Norman W. Flynn, Robert L. Dyer, Michael Anbar, Thomas Cairns, Shrikant Dighe, and Bernard E. Cabana
  J. Pharmacokin. Biopharm. 7, 233-248 (1979)
  [DOI: 10.1007/BF01060015] [PDF]
• Noncompartmental Determination of the Steady-State Volume of Distribution
  Leslie Z. Benet, Renato L. Galeazzi
  J. Pharm. Sci. 68, 1071-1074 (1979)
  [DOI: 10.1002/jps.2600680845] [PDF]
• Absorption and Disposition Kinetics of Amoxicillin in Normal Human Subjects
  A. Arancibia, J. Guttmann, G. Gonzalez, and C. Gonzalez
  Antimicrobial Agents and Chemotherapy 17, 199-202 (1980)
  [DOI: 10.1128/AAC.17.2.199] [PDF]
• A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes
  Meir Bialer
  J. Pharmacokin. Biopharm. 8, 111-113 (1980)
  [DOI: 10.1007/BF01059453] [PDF]
• History of pharmacokinetics
  John G. Wagner
  Pharmacol. Ther. 12, 537-562 (1981)
  [DOI: 10.1016/0163-7258(81)90097-8] [PDF]
• Metformin kinetics in healthy subjects and in patients with diabetes mellitus
  G.T. Tucker, C. Casey, P.J. Phillips, H. Connor, J.D. Ward & H.F. Woods
  Br. J. Clin. Pharmacol. 12, 235-246 (1981)
  [DOI: 10.1111/j.1365-2125.1981.tb01206.x] [PDF]
• Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations
  J. C. Rotschafer, K. Crossley, D. E. Zaske, K. Mead, R. J. Sawchuk, L. D. Solem
  Antimicrob. Agents Chemother. 22, 391-394 (1982)
  [DOI: 10.1128/AAC.22.3.391] [PDF]
• Clinical pharmacokinetics of dipyridamole
  Thorir D. Bjornsson, Cheryl Mahony
  Thrombosis Research 29, 93-104 (1983)
  [DOI: 10.1016/0049-3848(83)90364-X] [PDF]
• Clinical Pharmacokinetics of Systemic Antifungal Drugs
  T. K. Daneshmend & D. W. Warnock
  Clin. Pharmacokin. 8, 17-42 (1983)
  [DOI: 10.2165/00003088-198308010-00002] [PDF]
• Determination of Theophylline Bioavailability Using Saliva Theophylline Concentrations
  Donald L. Uden, Linda M. Strand, Kenneth W. Miller, and Darwin E. Zaske
  Pharmacotherapy 3, 235-238 (1983)
  [DOI: 10.1002/j.1875-9114.1983.tb03263.x] [PDF]
• Concentration Ratio Method to Determinethe Rate Constant for the Special Case when k_a = k_e
  Indravadan H. Patel
  J. Pharm. Sci. 73, 8591-861 (1984)
  [DOI: 10.1002/jps.2600730648] [PDF]
• Pharmacokinetics of Furosemide in Man After Intravenous and Oral Administration. Application of Moment Analysis
  M. M. Hammarlund, L. K. Paalzow, and B. Odlind
  Eur. J. Clin. Pharmacol. 26, 197-207 (1984)
  [DOI: 10.1007/BF00630286] [PDF]
• Clinical Pharmacokinetics of the Salicylates
  Christopher J. Needs & P. M. Brooks
  Clin. Pharmacokin. 10, 164-177 (1985)
  [DOI: 10.2165/00003088-198510020-00004] [PDF]
• INTRAV and ORAL: BASIC interactive computer programs for estimating pharmacokinetic parameters
  J. L. Valentine and Samuel Hunter
  J. Pharm. Sci. 74, 113-119 (1985)
  [DOI: 10.1002/jps.2600740202] [PDF]
• Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling
  Theresa A. Shepard, Richard H. Reuning, Leon J. Aarons
  J. Pharm. Sci. 74, 227-228 (1985)
  [DOI: 10.1002/jps.2600740228] [PDF]
• Time in review (editorial)
  Sharon D. Boots
  J. Pharm. Sci. 75, 1017 (1986)
  [DOI: 10.1002/jps.2600751102] [PDF]
• Time concepts in physics, biology, and pharmacokinetics
  Harold Boxenbaum
  J. Pharm. Sci. 75, 1053-1061 (1986)
  [DOI: 10.1002/jps.2600751107] [PDF]
• Reduced bioavailability and effect of furosemide given with food
  B. Beermann & C. Midskov
  Eur. J. Clin. Pharmacol. 29, 725-727 (1986)
  [DOI: 10.1007/BF00615967] [PDF]
• Bioavailability of paracetamol after oral administration to healthy volunteers. Influence of caffeine on rate and extent of absorption
  J. J. Tucker, J. M. A. Sitsen, Ch. F. Gusdorf
  Pharmaceutical Weekblad 8, 239-243 (1986)
  [DOI: 10.1007/BF01957785] [PDF]
• The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily
  J. K. Faulkner, D. McGibney, L. F. Chasseaud, J. L. Perry, I. W. Taylor
  Br. J. Clin. Pharmacol. 22, 21-25 (1986)
  [DOI: 10.1111/j.1365-2125.1986.tb02874.x] [PDF]
• Pharmacokinetics of flurbiprofen in man I. Area/dose relationships
  G. J. Szpunar, K. S. Albert, G. G. Bole, J. N. Dreyfus, G. F. Lockwood and J. G. Wagner
  Biopharm. Drug Disp. 8, 273-283 (1987)
  [DOI: 10.1002/bdd.2510080308] [PDF]
• Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: Comparison of single and multiple dose studies
  Zias Hussein, Meir Bialer, Michael Friedman, Itamar Raz
  Biopharm. Drug Disp. 8, 427-435 (1987)
  [DOI: 10.1002/bdd.2510080503] [PDF]
• Comparative bioavailability of a new sustained-release theophylline tablet
  Kenzo Takagi, Takako Watanabe, Tatsuo Satake, Takaaki Hasegawa, Yozo Ogura, Norishige Imaeda, Yuzo Mizukami
  Jpn. J. Allergol. 36, 1006-1011 (1987)
  [DOI: 10.15036/arerugi.36.1006] [PDF]
• Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans
  Ziad Hussein, Meir Bialer, Michael Friedman, Itamar Raz
  Int. J. Pharm. 37, 97-102 (1987)
  [DOI: 10.1016/0378-5173(87)90013-5] [PDF]
• Sustained Release Theophylline Preparations Practical Recommendations for Prescribing and Therapeutic Drug Monitoring
  Anne Glynn-Barnhart, Malcolm Hill and Stanley J. Szejler
  Drugs 35, 711-726 (1988)
  [DOI: 10.2165/00003495-198835060-00006] [PDF]
• Vancomycin pharmacokinetics in patients with various degrees of renal function
  K. A. Rodvold, R. A. Blum, J. H. Fischer, H. Z. Zokufa, J. C. Rotschafer, K. B. Crossley, L. J. Riff
  Antimicrob. Agents Chemother. 32, 848-852 (1988)
  [DOI: 10.1128/AAC.32.6.848] [PDF]
• Pharmacokinetics of Itraconazole following Oral Administration to Normal Volunteers
  Thomas C. Hardin, John R. Graybill, Richard Fetchick, R. Woestenborghs, Michael G. Rinaldi, and John G. Kuhn
  Antimicrob. Agents Chemother. 32, 1310-1313 (1988)
  [DOI: 10.1128/AAC.32.9.1310] [PDF]
• The pharmacokinetics of oxybutynin in man
  J. Douchamps, F. Derenne, A. Stockis, D. Gangji, M. Juvent & A. Herchuelz
  Eur. J. Clin. Pharmacol. 35, 515-520 (1988)
  [DOI: 10.1007/BF00558247] [PDF]
• The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets
  W. W. Arkinstall, M. Hopkinson, R. N. Rivington, L. Calcutt, T. Aitken, and J. H. Stewart
  J. Allergy Clin. Immun. 82, 155-164 (1988)
  [DOI: 10.1016/0091-6749(88)90994-3] [PDF]
• Release and absorption rate aspects of intramuscularly injected pharmaceuticals
  J. Zuidema, F.A.J.M. Pieters and G.S.M.J.E. Duchateau
  Int. J. Pharm. 47, 1-12 (1988)
  [DOI: 10.1016/0378-5173(88)90209-8] [PDF]
• Sustained-release theophylline preparations: Comment on "The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets"
  Miles M. Weinberger
  J. Allergy Clin. Immun. 85, 530 (1990)
  [DOI: 10.1016/0091-6749(90)90171-Y] [PDF]
• Reply to "Sustained-release theophylline preparations"
  Mark S. Dykewicz, Roy Patterson, Carol A. Wiggins
  J. Allergy Clin. Immun. 85, 530-531 (1990)
  [DOI: 10.1016/0091-6749(90)90172-Z] [PDF]
• Brief Report: Poor Bioavailability of Sustained-Release Theophylline. A Case for Liquid Theophylline
  Jonathan Corren, Anne Glynn-Barnhart
  J. Asthma 28, 57-60 (1991)
  [DOI: 10.3109/02770909109073372] [PDF]
• Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy
  R. Hartley, J. Aleksandrowicz, C. J. Bowmer, A. Cawood, W. I. Forsythe
  J. Pharm. Pharmacol. 43, 117-119 (1991)
  [DOI: 10.1111/j.2042-7158.1991.tb06644.x] [PDF]
• An Alternative Approach for Assessment of Rate of Absorption in Bioequivalence Studies
  Mei-Ling Chen
  Pharm. Res. 9, 1380-1385 (1992)
  [DOI: 10.1023/A:1015842425553] [PDF]
• Bioavailability of oral penicillins in the horse: a comparison of pivampicillin and amoxicillin
  J. M. Ensink, W. R. Klein, D. J. Mevius, A. Klarenbeek, A. G. Vulto
  Journal of Veterinary Pharmacology and Therapeutics 15, 221-230 (1992)
  [DOI: 10.1111/j.1365-2885.1992.tb01010.x] [PDF]
• High-Pressure Liquid Chromatographic Assay of Theophylline in Dog Feces following Oral Administration of Sustained-Release Products
  Andrew T. Chow, Patrick D. Meek, and Willian J. Jusko
  J. Pharm. Sci. 82, 956-958 (1993)
  [DOI: 10.1002/jps.2600820917] [PDF]
• Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation
  Edgar A. Mueller, John M. Kovarik, Johannes B. van Bree, Joachim Grevel, Peter W. Lucker & Klaus Kutz
  Pharm. Res. 11 151-155 (1994)
  [DOI: 10.1023/a:1018922517162] [PDF]
• Contribution of Superior Vena Caval Flow to Total Cardiac Output in Children. A Doppler Echocardiographic Study
  Mubadda A. Salim, Thomas G. DiSessa, Kristopher L. Arheart, and Bruce S. Alpert
  Circulation 92, 1860-1865 (1995)
  [DOI: 10.1161/01.cir.92.7.1860] [epub]
• Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
  G. Flesch, Ph. Müller, P. Lloyd
  Eur. J. Clin. Pharmacol. 52, 115-120 (1997)
  [DOI: 10.1007/s002280050259] [PDF]
• Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives
  L. Endrenyi, L. Tothfalusi
  Int. J. Clin. Pharmacol. Ther. 35, 142-150 (1997)
  [PubMed]
• FDA Guidance for Industry. Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations
  Venkata Ramana Uppoor et al.
  Dissolut. Technol. 4, 23-32 (1997)
  [DOI: 10.14227/DT040497P23] [PDF]
• Bioequivalence of immediate-release theophylline capsules
  Marvin C. Meyer, Eric J. Jarvi, Arthur B. Straughn, Francis R. Pelsor, Roger L. Williams and Vinod P. Shah
  Biopharm. Drug Disp. 20, 417-419 (1999)
  [DOI: 10.1002/1099-081X(199912)20:9<417::AID-BDD205>3.0.CO;2-W] [PDF]
• Mixed Effect Modeling of Sumatriptan Pharmacokinetics During Drug Development: II. From Healthy Subjects to Phase 2 Dose Ranging in Patients
  Valerie F. Cosson & Eliane Fuseau
  J. Pharmacokin and Biopharmac. 27, 149-171 (1999)
  [DOI: 10.1023/a:1020601906027] [PDF]
• Evaluation of Truncated Areas in the Assessment of Bioequivalence of Immediate Release Formulations of Drugs with Long Half-Lives and of Cmax with Different Dissolution Rates
  Pradeep Sathe, Jurgen Venitz, Lawrence Lesko
  Pharm. Res. 16, 939-943 (1999)
  [DOI: 10.1023/A:1018898624643] [PDF]
• A compartmental absorption and transit model for estimating oral drug absorption
  Lawrence X. Yu, Gordon L. Amidon
  Int. J. Pharm. 186, 119-125 (1999)
  [DOI: 10.1016/s0378-5173(99)00147-7] [PDF]
• Clinical pharmacokinetics of pioglitazone
  D. A. Eckland, M. Danhof
  Exp. Clin. Endocrinol. Diabetes 108, S234-242 (2000)
  [DOI: 10.1055/s-2000-8525] [PDF]
• Carbamazepine Level-A In Vivo-In Vitro Correlation (IVIVC): A Scaled Convolution Based Predictive Approach
  P. Veng-Pedersen, J.V.S. Gobburu, M.C. Meyer and A.B. Straughn
  Biopharm. Drug Disp. 21, 1-6 (2000)
  [DOI: 10.1002/1099-081x(200001)21:1<1::aid-bdd207>3.0.co;2-d] [PDF]
• Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patient
  J Stangier, CAPF Su, and W Roth
  J. Int. Med. Res. 28, 149-167 (2000)
  [DOI: 10.1177/147323000002800401] [PDF]
• Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers
  Mark Dershwitz, John L. Walsh, Richard J. Morishige, Patricia M. Connors, Reid M. Rubsamen, Steven L. Shafer, Carl E. Rosow
  Anesthesiology 93, 619-628 (2000)
  [DOI: 10.1097/00000542-200009000-00009] [PDF]
• A Population Pharmacokinetic Model That Describes Multiple Peaks Due to Enterohepatic Recirculation of Ezetimibe
  Farkad Ezet, Gopal Krishna, David B. Wexler, Paul Statkevich, Teddy Kosoglou, and Vijay K. Batra,
  Clinical Therapeutics 23, 871-885 (2001)
  [DOI: 10.1016/S0149-2918(01)80075-8] [PDF]
• Digoxin Bioequivalency Reviews (76268)
  (2002)
  [Source: PDF] [PDF]
• Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation
  Julraht Konsil, Somchit Dechasathian, David H. Mason, Jr., Ruth E. Stevens
  J. Pharm. Pharmaceut. Sci. 5, 169-175 (2002)
  [Source: JPPS] [PDF]
• Absolute Bioavailability, Pharmacokinetics, and Urinary Excretion of the Novel Antimigraine Agent Almotriptan in Healthy Male Volunteers
  Josep M. Jansat, Joan Costa, Pau Salva, Francisco J. Fernandez, and Antonio Martinez-Tobed
  J. Pharmacokin. Pharmacodyn. 42, 1303-1310 (2002)
  [DOI: 10.1177/0091270002239359] [PDF]
• Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate
  Gary J Muirhead, David J Rance, Donald K Walker, and Philip Wastall
  Br. J. Clin. Pharmacol. 53, 13S-20S (2002)
  [DOI: 10.1046/j.0306-5251.2001.00028.x] [PDF]
• Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults
  Rachel Courtney, Sudhakar Pai, Mark Laughlin, Josephine Lim, and Vijay Batra
  J. Antimicrob. Chemother. 47, 2788-2795 (2003)
  [DOI: 10.1128/AAC.47.9.2788-2795.2003] [PDF]
• Pharmacokinetics of Methylphenidate After Oral Administration of Two Modified-Release Formulations in Healthy Adults
  John S. Markowitz, Arthur B. Straughn, Kennerly S. Patrick, C. Lindsay DeVane, Linda Pestreich, James Lee, Yanfeng Wang & Rafael Muniz
  Clin. Pharmacokinet. 42, 393-401 (2003)
  [DOI: 10.2165/00003088-200342040-00007] [PDF]
• Pharmacokinetics and Metabolism of Transdermal Oxybutynin In Vitro and in Vivo Performance of a Novel Delivery System
  R. Howard Zobrist, Danyi Quan, Heather M. Thomas, Stephanie Stanworth, and Steven W. Sanders
  Pharm. Res. 20, 103-109 (2003)
  [DOI: 10.1023/A:1022259011052] [PDF]
• Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: bioequivalence of the new Sigmasporin Microoral and Sandimmun Neoral
  Naji M. Najib, Nasir Idkaidek, Ayman Adel, B. Mohammed, Sahar Al-Masri, Isra' Admour, S. Mahmood Alam, Ruwayda Dham, Qumaruzaman
  Eur. J. Pharm. Biopharm. 55, 67-70 (2003)
  [DOI: 10.1016/S0939-6411(02)00157-1] [PDF]
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
  Chi-Yuan Wu & Leslie Z. Benet
  Pharm. Res. 22, 11-23 (2005)
  [DOI: 10.1007/s11095-004-9004-4] [PDF]
• Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis
  Paul Beringer, Kitty My Tu Huynh, Jane Kriengkauykiat, Luke Bi, Nils Hoem, Stan Louie, Emily Han, Thao Nguyen, Donald Hsu, Purush A. Rao, Bertrand Shapiro, and Mark Gill
  Antimicrob. Agents Chemother. 49, 5013-5017 (2005)
  [DOI: 10.1128/AAC.49.12.5013-5017.2005] [PDF]
• In vitro - In vivo Correlation: From Theory to Applications
  Jaber Emami
  J. Pharm. Pharmaceut. Sci. 9, 31-51 (2006)
  [Source: JPPS] [PDF]
• Dissolution Profiles of Three Brands of Lamivudine and Zidovudine Combinations in the Nigerian Market
  N. A. Ochekpe, N. C. Ngwuluka, H. Owolayo, T. Fashedemi
  Dissolut. Technol. 13, 12-17 (2006)
  [DOI: 10.14227/DT130406P12] [PDF]
• Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
  Radojka M. Savic, Daniël M. Jonker, Thomas Kerbusch, Mats O. Karlsson
  J. Pharmacokin. Pharmacodyn. 34, 711-726 (2007)
  [DOI: 10.1007/s10928-007-9066-0] [PDF]
• Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats
  Tomoyuki Furubayashi, Akiko Kamaguchi, Kazushi Kawaharada, Yoshie Masaoka, Makoto Kataoka, Shinji Yamashita, Yutaka Higashi, Toshiyasu Sakane
  Biol. Pharm. Bull. 30, 608-611 (2007)
  [DOI: 10.1248/bpb.30.608] [PDF]
• Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers
  Jonathonm Dowling, Geoffrey K. Isbister, Carl M. J. Kirkpatrick, Daya Naidoo, and Andis Graudins
  Ther. Drug Monit. 30, 490-496 (2008)
  [DOI: 10.1097/FTD.0b013e3181816214] [PDF]
• Solubility and Dissolution Rate Determination of Different Antiretroviral Drugs in Different pH Media Using UV Visible Spectrophotometer
  K. Prakash, P. Narayana Raju , K. Shanta Kumari, and M. Lakshmi Narasu
  E-Journal of Chemistry 5, 1159-1164 (2008)
  [DOI: 10.1155/2008/125917] [PDF]
• Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics
  M. Bergstrand, E. Soderlind, W. Weitschies, M. O. Karlsson
  Clin. Pharmacol. Therap. 86, 77-83 (2009)
  [DOI: 10.1038/clpt.2009.43] [PDF]
• Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers
  Ney Carter do Carmo Borges, Rafael Barrientos Astigarraga, Carlos Eduardo Sverdloff, Bruno Carter Borges, Thais Rodrigues Paiva, Paulo Rebelo Galvinas, Ronilson Agnaldo Moreno
  J. Chromatography B 879, 236-242 (2010)
  [DOI: 10.1016/j.jchromb.2010.12.003] [PDF]
• Bioequivalence: tried and tested
  Robert Schall, Laszlo Endrenyi
  Cardiovasc. J. Afr. 21, 69-71 (2010)
  [Source] [PDF]
• Investigation of bioequivalence
  EMA
  (2010)
  [Source] [PDF]
• Physiological Parameters for Oral Delivery and in Vitro Testing
  Deanna M. Mudie, Gordon L. Amidon, and Gregory E. Amidon
  Mol. Pharm. 7, 1388-1405 (2010)
  [DOI: 10.1021/mp100149j] [PDF]
• Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs
  H. Kortejärvi, R. Shawahna, A. Koski, J. Malkki, K. Ojala, M. Yliperttula
  J. Pharm. Sci. 99, 621-625 (2010)
  [DOI: 10.1002/jps.21879] [PDF]
• Mathematical Expressions of the Pharmacokinetic and Pharmacodynamic Models implemented in the PFIM software
  Anne Dubois, Julie Bertrand and France Mentré
  UMR738, INSERM, University Paris Diderot (2011)
  [PDF]
• Flip-flop pharmacokinetics delivering a reversal of disposition: challenges and opportunities during drug development
  Jaime A Yanez, Connie M Remsberg, Casey L Sayre, M Laird Forrest & Neal M Davies
  Therapeutic Delivery 2, 643-672 (2011)
  [DOI: 10.4155/tde.11.19] [PDF]
• Evaluation of In Vitro Equivalence for Drugs Containing BCS Class II Compound Ketoprofen
  E. Shohin, J. I. Kulinich, G. V. Ramenskaya, and G. F. Vasilenko
  Dissolut. Technol. 18, 26-29 (2011)
  [DOI: 10.14227/DT180111P26] [PDF]
• Population Pharmacokinetic Model of Human Insulin Following Different Routes of Administration
  Elizabeth Potocka, Robert A. Baughman, and Hartmut Derendorf
  J. Clin. Pharmacol. 51, 1015-1024 (2011)
  [DOI: 10.1177/0091270010378520] [PDF]
• Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial
  Li Sun, Hankun Li, Kenneth Willson, Sheila Breidinger, Matthew L. Rizk, Larissa Wenning, Eric J. Woolf
  Anal. Chem. 84, 8614-8621 (2012)
  [DOI: 10.1021/ac301581h] [PDF]
• Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
  David W. Boulton, Sreeneeranj Kasichayanula, Chi Fung (Anther) Keung, Mark E. Arnold, Lisa J. Christopher, Xiaohui (Sophia) Xu, and Frank LaCreta
  Br. J. Clin. Pharmacol. 75, 763-768 (2012)
  [DOI: 10.1111/j.1365-2125.2012.04391.x] [PDF]
• Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers
  S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, Deborah L. Miller, Lucas van Bortel, Kenneth C. Lasseter, Barnali Pramanik, Caroline Cilissen, Qi Liu, Lida Liu, Boyd B. Scott, Deborah Panebianco, Yu Ding, Keith Gottesdiener & John A. Wagner
  Br. J. Clin. Pharmacol. 75, 1240-1254 (2012)
  [DOI: 10.1111/j.1365-2125.2012.04471.x] [PDF]
• A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations
  Martin Bergstrand, Erik Soderlind, Ulf G. Eriksson, Werner Weitschies & Mats O. Karlsson
  Pharm. Res. 29, 574-584 (2012)
  [DOI: 10.1007/s11095-011-0595-2] [PDF]
• A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations
  Martin Bergstrand, Erik Soderlind, Ulf G. Eriksson, Werner Weitschies, Mats O. Karlsson
  Pharm. Res. 29, 695-706 (2012)
  [DOI: 10.1007/s11095-011-0594-3] [PDF]
• A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
  G. Krishna, L. Ma, M.Martinho, R. A. Preston and E. O'Mara
  J. Antimicrob. Chemother. 67, 2725-2730 (2012)
  [DOI: 10.1093/jac/dks268] [PDF]
• Influence of electrostatic heteroaggregation of lipid droplets on their stability and digestibility under simulated gastrointestinal conditions
  Yingyi Mao and David Julian McClements
  Food Funct. 3, 1025-1034 (2012)
  [DOI: 10.1039/c2fo30108c] [PDF]
• Steady-State Carbamazepine Pharmacokinetics Following Oral and Stable-Labeled Intravenous Administration in Epilepsy Patients: Effects of Race and Sex
  S. E. Marino, A. K. Birnbaum, I. E. Leppik, J. M. Conway, L. C. Musib, R. C. Brundage, R. E. Ramsay, P. B. Pennell, J. R. White, C. R. Gross, J. O. Rarick, U. Mishra, J. C. Cloyd
  Clin. Pharmacol. Therap. 91, 483-488 (2012)
  [DOI: 10.1038/clpt.2011.251] [PDF]
• Population pharmacokinetics of abacavir in infants, toddlers and children
  Wei Zhao, Chiara Piana, Meindert Danhof, David Burger, Oscar Della Pasqua, & Evelyne Jacqz-Aigrain
  Br. J. Clin. Pharmacol. 75, 1525-1535 (2012)
  [DOI: 10.1111/bcp.12024] [PDF]
• In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim
  Erik Sjogren, Jan Westergren, Iain Grant, Gunilla Hanisch, Lennart Lindfors, Hans Lennernas, Bertil Abrahamsson, Christer Tannergren
  Eur. J. Pharm. Sci. 49, 679-698 (2013)
  [DOI: 10.1016/j.ejps.2013.05.019] [PDF]
• Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug
  Jonathan Brown, Caly Chien, Peter Timmins, Andrew Dennis, Walter Doll, Erik Sandefer, Richard Page, Richard E. Nettles, Li Zhu, Dennis Grasela
  J. Pharm. Sci. 102, 1742-1751 (2013)
  [DOI: 10.1002/jps.23476] [PDF]
• Application of permeability-limited physiologically-based pharmacokinetic models: Part I-Digoxin Pharmacokinetics Incorporating P-Glycoprotein-Mediated Efflux
  Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner, Amin Rostami-Hodjegan
  J. Pharm. Sci. 102, 3145-3160 (2013)
  [DOI: 10.1002/jps.23594] [PDF]
• Application of permeability-limited physiologically-based pharmacokinetic models: Part II-prediction of p-glycoprotein mediated drug-drug interactions with digoxin
  Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner, Amin Rostami-Hodjegan
  J. Pharm. Sci. 102, 3161-3173 (2013)
  [DOI: 10.1002/jps.23607] [PDF]
• A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men
  Jung-woo Chae, Jeong-won Seo, Bimit Mahat, Hwi-yeol Yun, In-hwan Baek, Byung-yo Lee, Dong-hyun Kim & Kwang-il Kwon
  Drug Developm. Ind. Pharmacy 40, 1325-1329 (2013)
  [DOI: 10.3109/03639045.2013.819880] [PDF]
• Population pharmacokinetic analysis of axitinib in healthy volunteers
  May Garrett, Bill Poland, Meghan Brennan, Brian Hee, Yazdi K. Pithavala & Michael A. Amantea
  Br. J. Clin. Pharmacol. 77, 480-492 (2013)
  [DOI: 10.1111/bcp.12206] [PDF]
• Paediatric pharmacokinetics: key considerations
  Hannah Katharine Batchelor and John Francis Marriott
  Br. J. Clin. Pharmacol. 79, 395-404 (2013)
  [DOI: 10.1111/bcp.12267] [PDF]
• Single- and Multiple-Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase-2, in Man
  Nancy G. B. Agrawal, Arturo G. Porras, Catherine Z. Matthews, Mark J. Rose, Eric J. Woolf, Bret J. Musser, Andrea L. Dynder, Katherine E. Mazina, Kenneth C. Lasseter, Thomas L. Hunt, Jules I. Schwartz, Jacqueline B. McCrea, Keith M. Gottesdiener
  J. Clin. Pharmacol. 43, 268-276 (2013)
  [DOI: 10.1177/0091270003251122] [PDF]
• Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
  Heino Stass, Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann
  Clin. Drug Investig. 33, 419-427 (2013)
  [DOI: 10.1007/s40261-013-0082-0] [PDF]
• PBPK models for the prediction of in vivo performance of oral dosage forms
  Edmund S. Kostewicz, Leon Aarons, Martin Bergstrand, Michael B. Bolger, Aleksandra Galetin, Oliver Hatley, Masoud Jamei, Richard Lloyd, Xavier Pepin, Amin Rostami-Hodjegan, Erik Sjogren, Christer Tannergren, David B. Turner, Christian Wagner, Werner Weitschies, Jennifer Dressman
  Eur. J. Pharm. Sci. 57, 300-321 (2014)
  [DOI: 10.1016/j.ejps.2013.09.008] [PDF]
• In vitro models for the prediction of in vivo performance of oral dosage forms
  Edmund S. Kostewicz, Bertil Abrahamsson, Marcus Brewster, Joachim Brouwers, James Butler, Sara Carlert, Paul A. Dickinson, Jennifer Dressman, Rene Holm, Sandra Klein, James Mann, Mark McAllister, Mans Minekus, Uwe Muenster, Anette Mullertz, Miriam Verwei, Maria Vertzoni, Werner Weitschies, Patrick Augustijns
  Eur. J. Pharm. Sci. 57, 342-366 (2014)
  [DOI: 10.1016/j.ejps.2013.08.024] [PDF]
• Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations
  Nina Brvar, Tatjana Mateovic-Rojnik, Iztok Grabnar
  Int. J. Pharm. 473, 170-178 (2014)
  [DOI: 10.1016/j.ijpharm.2014.07.013] [PDF]
• Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State
  Deanna M. Mudie, Kathryn Murray, Caroline L. Hoad, Susan E. Pritchard, Martin C. Garnett, Gordon L. Amidon, Penny A. Gowland, Robin C. Spiller, Gregory E. Amidon, and Luca Marciani
  Mol. Pharm. 11, 3039-3047 (2014)
  [DOI: 10.1021/mp500210c] [PDF]
• A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia
  Adriaan Cleton, Stefaan Rossenu, Herta Crauwels, Joris Berwaerts, David Hough, Srihari Gopal, Marielle Eerdekens, An Vandebosch, Bart Remmerie, Marc De Meulder, and Clara M. Rosso
  J. Clin. Pharmacol. 54, 1048-1057 (2014)
  [DOI: 10.1002/jcph.295] [PDF]
• Development of In Vitro-In Vivo Correlation for Extended Release Niacin After Administration of Hypromellose Based Matrix Formulations to Healthy Volunteers
  Filippos Kesisoglou, Stefaan Rossenu, Colm Farrell, Michiel van den Heuvel, Marita Prohn, Shaun Fitzpatrick, Pieter-Jan de Kam, Ryan Vargo
  J. Pharm. Sci. 103, 3713-3723 (2014)
  [DOI: 10.1002/jps.24179] [PDF]
• In Vitro-In Vivo Correlation Strategy Applied to an Immediate-Release Solid Oral Dosage Form with a Biopharmaceutical Classification System IV Compound Case Study
  Gerard M. Bredael, Niya Bowers, Fabien Boulineau, David Hahn
  J. Pharm. Sci. 103, 2125-2130 (2014)
  [DOI: 10.1002/jps.24036] [PDF]
• Sitagliptin Phosphate: Development of a Dissolution Method for Coated Tablets Based on In Vivo Data for Improving Medium Sensitivity
  Alini Dall Cortivo Lange, Ana Paula Batistel, Leticia Lenz Sfair, Jaison Carlosso, Nadia Maria Volpato, and Elfrides Eva Scherman Schapoval
  Dissolut. Technol. 21, 17-22 (2014)
  [DOI: 10.14227/DT210214P17] [PDF]
• Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration
  Hartley C. Atkinson, Ioana Stanescu, Chris Frampton, Isam I. Salem, Charles P. H. Beasleyr, Richard Robson
  Clin. Drug Investig. 35, 625-632 (2015)
  [DOI: 10.1007/s40261-015-0320-8] [PDF]
• Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm
  Filippos Kesisoglou and Amitava Mitra
  AAPS J. 17, 1224-1236 (2015)
  [DOI: 10.1208/s12248-015-9781-1] [PDF]
• Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects
  Thierry Wendling, Kayode Ogungbenro, Etienne Pigeolet, Swati Dumitras, Ralph Woessner & Leon Aarons
  Pharm. Res. 32, 1764-1778 (2015)
  [DOI: 10.1007/s11095-014-1574-1] [PDF]
• Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate
  Filippos Kesisoglou, Binfeng Xia, and Nancy G. B. Agrawal
  AAPS J. 17, 1492-1500 (2015)
  [DOI: 10.1208/s12248-015-9816-7] [PDF]
• Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls
  Filippos Kesisoglou, Andre Hermans, Colleen Neu, Ka Lai Yee, John Palcza, Jessica Miller
  J. Pharm. Sci. 104, 2913-2922 (2015)
  [DOI: 10.1002/jps.24362] [PDF]
• Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS
  Kimberly L. Garrison, Selma Sahin, Leslie Z. Benet
  J. Pharm. Sci. 104, 3229-3235 (2015)
  [DOI: 10.1002/jps.24505] [PDF]
• Transdermal patches: history, development and pharmacology
  Michael N. Pastore, Yogeshvar N. Kalia, Michael Horstmann and Michael S. Roberts
  Br. J. Pharmacol. 172, 22179-2209 (2015)
  [DOI: 10.1111/bph.13059] [PDF]
• Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
  Jennifer E. Sager, Jingjing Yu, Isabelle Ragueneau-Majlessi, and Nina Isoherranen
  Drug Metab. Disp. 43, 1823-1837 (2015)
  [DOI: 10.1124/dmd.115.065920] [PDF]
• Safety assessment of Efavirenz after a single-dose bioequivalence study : a trend to correlate central nervous system effect and plasma concentrations
  Marta Vázquez, Pietro Fagiolino, Manuel Ibarra, Laura Magallanes
  Int. J. Pharm. 5, 46-52 (2015)
  [https://www.pharmascholars.com/abstract/safety-assessment-of-efavirenz-after-a-singledose-bioequivalence-study-a-trend-to-correlate-central-nervous-system-effec-51194.html] [PDF]
• Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs
  Jens Markus Borghardt, Benjamin Weber, Alexander Staab, and Charlotte Kloft
  AAPS J. 17, 853-870 (2015)
  [DOI: 10.1208/s12248-015-9760-6] [PDF]
• Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system
  Wei Gong, Yan Liu, Dan-Yu Mei, Meiyan Yang, Xing-Guo Mei
  Drug Dev. Ind. Pharm. 41, 464-469 (2015)
  [DOI: 10.3109/03639045.2013.877923] [PDF]
• Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
  Yvonne Y. Lau, Wen Gu, Tiffany Lin, Dongweon Song, Richard Yu, and Jeffrey W. Scott
  J. Clin. Pharmacol. 56, 559-566 (2016)
  [DOI: 10.1002/jcph.619] [PDF]
• Kaleo briefing on naloxone HCl
  (2016)
  [Source: FDA] [PDF]
• Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions
  Alison Margolskee, Adam S. Darwich, Aleksandra Galetin, Amin Rostami-Hodjegan & Leon Aarons
  AAPS J. 18, 321-332 (2016)
  [DOI: 10.1208/s12248-015-9849-y] [PDF]
• A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time
  Ahmad Y. Abuhelwa, David J. R. Foster, and Richard N. Upton
  AAPS J. 18, 1322-1333 (2016)
  [DOI: 10.1208/s12248-016-9953-7] [PDF]
• Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption
  Filippos Kesisoglou, Anand Balakrishnan, Kimberly Manser
  J. Pharm. Sci. 105, 722-728 (2016)
  [DOI: 10.1002/jps.24674] [PDF]
• Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose
  Philip Krieter, Nora Chiang, Shwe Gyaw, Phil Skolnick, Roger Crystal, Fintan Keegan, Julie Aker, Melissa Beck, and Jennifer Harris
  J. Clin. Pharmacol. 56, 1243-1253 (2016)
  [DOI: 10.1002/jcph.759] [PDF]
• Evzio (naloxone hydrochloride injection) Auto-injector for intramuscular or subcutaneous use
  
  FDA , 4001455 (2016)
  [DOI: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209862lbl.pdf] [PDF]
• Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS ® Formulation of Oxybutynin
  Andres Olivares-Morales, Avijit Ghosh, Leon Aarons, Amin Rostami-Hodjegan
  AAPS J. 18, 1532 (2016)
  [DOI: 10.1208/s12248-016-9965-3] [PDF]
• The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women
  Stefan Zajic, Stefaan Rossenu, David Hreniuk, Filippos Kesisoglou, Jacqueline McCrea, Fang Liu, Li Sun, Rose Witter, Don Gauthier, Roy Helmy, Darrick Joss, Tong Ni, Randall Stoltz, Julie Stone and S. Aubrey Stoch
  Drug Metabolism and Disposition 44, 1450-1458 (2016)
  [DOI: 10.1124/dmd.116.069906] [PDF]
• Modifications of the Method for Calculating Absolute Drug Bioavailability
  Wei Jiang, Juan-juan Yang, Lei Cao, Xue Xiao, Xiao-lian Shi, Yong-xiao Cao
  J. Pharm. Pharm. Sci. 19, 181-187 (2016)
  [DOI: 10.18433/J3RG78] [PDF]
• Altered Doppler flow patterns in cirrhosis patients: an overview
  Pooya Iranpour, Chandana Lall, Roozbeh Houshyar, Mohammad Helmy, Albert Yang, Joon-Il Choi, Garrett Ward, Scott C Goodwin
  Ultrasonography 35, 3-12 (2016)
  [DOI: 10.14366/usg.15020] [PDF]
• A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables
  Mahadevabharath R. Somayaji, Debarun Das, Andrzej Przekwas
  Clin. Pharmacokinet. 55, 1179-1190 (2016)
  [DOI: 10.1007/s40262-016-0388-1] [PDF]
• Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation
  H. G. Bone, M. A. Walter, M. E. Hurley, S. Epstein
  Osteoporos Int. 28, 1745-1752 (2017)
  [DOI: 10.1007/s00198-017-3941-3] [PDF]
• Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal
  Gill Mundin, Rebecca McDonald, Kevin Smith, Stephen Harris, John Strang
  Addiction 112, 1647-1652 (2017)
  [DOI: 10.1111/add.13849] [PDF]
• Pharmacokinetics of a new, nasal formulation of naloxone
  Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen, Sissel Skarra, Phatsawee Jansook & Ola Dale
  Eur. J. Clin. Pharmacol. 73, 555-562 (2017)
  [DOI: 10.1007/s00228-016-2191-1] [PDF]
• Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation
  Rajendar K. Mittapalli, Silpa Nuthalapati, Alyssa E. Delke DeBord, Hao Xiong
  Pharm. Res. 34, 1187-1192 (2017)
  [DOI: 10.1007/s11095-017-2133-3] [PDF]
• Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study
  Disala Fernando, Sarah Siederer, Sunita Singh, Ian Schneider, Ashutosh Gupta, Marcy Powell, Duncan Richards, Michelle P. McIntosh, Peter Lambert, Susan Fowles
  EBioMedicine 22, 249-255 (2017)
  [DOI: 10.1016/j.ebiom.2017.07.020] [PDF]
• Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
  Louis Lin and Harvey Wong
  Pharmaceutics 9, 41 (2017)
  [DOI: 10.3390/pharmaceutics9040041] [PDF]
• Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies
  BT Gufford, GR Ainslie, JR White Jr, ME Layton, JM Padowski, GM Pollack and MF Paine
  Clin. Transl. Sci. 10, 380-386 (2017)
  [DOI: 10.1111/cts.12473] [PDF]
• International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database
  Rebecca McDonald, Oyvind Danielsson Glende, Ola Dale, John Strang
  Drug Alcohol Rev. 37, 205-215 (2017)
  [DOI: 10.1111/dar.12571] [PDF]
• Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers
  E. Vanky, L. Hellmundt, U. Bondesson, S. Eksborg and S. Lundeberg
  Acta Anaesthesiologica Scandinavica 61, 636-640 (2017)
  [DOI: 10.1111/aas.12898] [PDF]
• IVIVC approach based on carbamazepine bioequivalence studies combination
  I. González-García, V. Mangas-Sanjuan, M. Merino-Sanjuán, C. Álvarez-Álvarez, J. Díaz-Garzón Marco, M. A. Rodríguez-Bonnín, T. Langguth, J. J. Torrado-Durán, P. Langguth, A. García-Arieta, M. Bermejo
  Pharmazie 72, 449-457 (2017)
  [DOI: 10.1691/ph.2017.7011] [PDF]
• A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives
  M.A. Nguyen, T. Flanagan, M. Brewster, F. Kesisoglou, S. Beato, J. Biewenga, J. Crison, R. Holm, R. Li, E. Mannaert, M. McAllister, M. Mueller-Zsigmondy, U. Muenster, K. Ojala, S. Page, A. Parr, S. Rossenu, P. Timmins, A. Van Peer, A. Vermeulen, P. Langguth
  Eur. J. Pharm. Sci. 102, 1-13 (2017)
  [DOI: 10.1016/j.ejps.2017.02.029] [PDF]
• In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: A historical review
  Aude Pestieau, Brigitte Evrard
  Eur. J. Pharm. Sci. 102, 203-219 (2017)
  [DOI: 10.1016/j.ejps.2017.03.019] [PDF]
• Investigating Oral Absorption of Carbamazepine in Pediatric Populations
  Philip Kohlmann, Cordula Stillhart, Martin Kuentz, Neil Parrott
  AAPS J. 19, 1864-1877 (2017)
  [DOI: 10.1208/s12248-017-0149-6] [PDF]
• Population pharmacokinetics of exenatide
  Population pharmacokinetics of exenatide
  Br. J. Clin. Pharmacol. 83, 517-526 (2017)
  [DOI: 10.1111/bcp.13135] [PDF]
• Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study
  Rebecca McDonald, Ulrike Lorch, Jo Woodward, Bjorn Bosse, Helen Dooner, Gill Mundin, Kevin Smith, John Strang
  Addiction 113, 484-493 (2018)
  [DOI: 10.1111/add.14033] [PDF]
• Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs
  Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke A. Wittenburg
  Can. J. Vet. Res. 82, 178-183 (2018)
  [PMCID: PMC6038833] [PDF]
• Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers
  Arne Kristian Skulberg, Ida Tylleskar, Turid Nilsen, Sissel Skarra, Oyvind Salvesen, Trond Sand, Thorsteinn Loftsson & Ola Dale
  Eur. J. Clin. Pharmacol. 74, 873-883 (2018)
  [DOI: 10.1007/s00228-018-2443-3] [PDF]
• Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients
  L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens, J. H. Beijnen
  Cancer Chemotherapy and Pharmacology 81, 39-46 (2018)
  [DOI: 10.1007/s00280-017-3455-x] [PDF]
• Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
  Sangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, Alfin Vaz, Haihong Shi, Eric Fluhler, Eric J. Woolf, Klaas Schildknegt, Kyle Matschke, Christine Alvey, Susan Zhou, Dimitris Papadopoulos, Robert Fountaine, Didier Saur, Steven G. Terra, Lloyd Stevens, Daniel Gaunt and David L. Cutler
  Clin. Transl. Sci. 11, 405-411 (2018)
  [DOI: 10.1111/cts.12549] [PDF]
• A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
  Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O'Sullivan
  Front. Pharmacol. 9, 1365 (2018)
  [DOI: 10.3389/fphar.2018.01365] [PDF]
• Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men
  Ka Lai Yee, Jacqueline McCrea, Deborah Panebianco, Wen Liu, Nicole Lewis, Tamara Cabalu, Steven Ramael, Rebecca E. Wrishko
  Clin. Drug Investig. 38, 631-638 (2018)
  [DOI: 10.1007/s40261-018-0650-4] [PDF]
• In vitro dissolution as a tool for formulation selection: Telmisartan two-step IVIVC
  Alejandro Ruiz-Picazo, M^a Teresa Martinez-Martinez, Sarin Colon-Useche, Ramon Iriarte, Barbara Sanchez-Dengra, Marta Gonzalez-Alvarez, Alfredo Garcia-Arieta, Isabel Gonzalez Alvarez, and Marival Bermejo
  Mol. Pharmaceutics 15, 2307-2315 (2018)
  [DOI: 10.1021/acs.molpharmaceut.8b00153] [PDF]
• Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach
  Jean Michel Cardot, John C Lukas, Paula Muniz
  AAPS J. 20, 95 (2018)
  [DOI: 10.1208/s12248-018-0250-5] [PDF]
• Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation
  I. Gonzalez-Garcia, A. Garcia-Arieta, M. Merino-Sanjuan, V. Mangas-Sanjuan, M. Bermejo
  Eur. J. Pharm. Sci. 119, 200-207 (2018)
  [DOI: 10.1016/j.ejps.2018.04.025] [PDF]
• Pharmaceutical Equivalence and Similarity Studies of Metoclopramide Tablets
  Maria A. Varillas, Marta I.V. Brevedan, Noelia L. Gonzalez Vidal
  Dissolut. Technol. 25, 14-21 (2018)
  [DOI: 10.14227/DT250118P14] [PDF]
• On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe
  Konstantina Soulele & Vangelis Karalis
  Xenobiotica 49, 446-456 (2018)
  [DOI: 10.1080/00498254.2018.1463117] [PDF]
• In Vitro Dissolution Testing to Assess Pharmaceutical Equivalence of Selected Amoxicillin Products Available in Sri Lanka: A Post-Marketing Study
  Dhanusha Thambavita, Charith M. Jayathilake, K. D. Darshi Sandamali, Priyadarshani Galappatthy, and Raveendra Laal Jayakody
  Dissolut. Technol. 26, 56-61 (2019)
  [DOI: 10.14227/DT260119P56] [PDF]
• Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device
  Philip A. Krieter, Nora Chiang, Shwe Gyaw, and David J. McCann
  J. Clin. Pharmacol. 59, 1078-1084 (2019)
  [DOI: 10.1002/jcph.1401] [PDF]
• Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose - a randomized controlled trial
  Arne Kristian Skulberg, Anders Asberg, Hasse Zare Khiabani, Hilde Rostad, Ida Tylleskar, Ola Dale
  Addiction 114, 859-867 (2019)
  [DOI: 10.1111/add.14552] [PDF]
• Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial
  Paul Dietze, Marianne Jauncey, Allison Salmon, Mohammadreza Mohebbi, Julie Latimer, Ingrid van Beek, Colette McGrath, Debra Kerr
  JAMA Network Open 2, e1914977 (2019)
  [DOI: 10.1001/jamanetworkopen.2019.14977] [PDF]
• Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs
  Brandon M. Wahler, Phillip Lerche, Carolina H. Ricco Pereira, Richard M. Bednarski, Butch KuKanich, Jeffrey Lakritz, and Turi K. Aarnes
  Am. J. Vet. Res. 80, 696-701 (2019)
  [DOI: 10.2460/ajvr.80.7.696] [PDF]
• Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
  Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen, Sissel Skarra, Ola Dale
  Tidsskr. Nor. Laegeforen. 139, (13) (2019)
  [DOI: 10.4045/tidsskr.19.0162] [PDF]
• In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration
  James Butler, Bart Hens, Maria Vertzoni, Joachim Brouwers, Philippe Berben, Jennifer Dressman, Cord J. Andreas, Kerstin Julia Schaefer, James Mann, Mark McAllister, Masoud Jamei, Edmund Kostewicz, Filippos Kesisoglou, Peter Langguth, Mans Minekus, Anette Mullertz, Ronald Schilderink, Mirko Koziolek, Philipp Jedamzik, Werner Weitschies, Christos Reppas, Patrick Augustijns
  Eur. J. Pharm. Biopharm. 136, 70-83 (2019)
  [DOI: 10.1016/j.ejpb.2018.12.010] [PDF]
• Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers
  Timothy M Rawson, Sally A N Gowers, David M E Freeman, Richard C Wilson, Sanjiv Sharma, Mark Gilchrist, Alasdair MacGowan, Andrew Lovering, Mark Bayliss, Mathew Kyriakides, Pantelis Georgiou, Anthony E G Cass, Danny O'Hare, Alison H Holmes
  The Lancet Digital Health 1, e335-e343 (2019)
  [DOI: 10.1016/S2589-7500(19)30131-1] [PDF]
• Integration of precipitation kinetics from an in vitro, multicompartment transfer system and mechanistic oral absorption modeling pharmacokinetic prediction of weakly basic drugs
  Sanjaykumar Patel, WeiZhu, Binfeng Xia, Navneet Sharma, Andre Hermans, Jason D. Ehrick, Filippos Kesisoglou, Justin Pennington
  J. Pharm. Sci. 108, 574-583 (2019)
  [DOI: 10.1016/j.xphs.2018.10.051] [PDF]
• Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite
  K. Soulele, V. Karalis
  Eur. J. Pharm. Sci. 128, 18-26 (2019)
  [DOI: 10.1016/j.ejpb.2018.12.018] [PDF]
• Mechanistic PBPK Modeling of the Dissolution and Food Effect of a BCS IV Compound - the Venetoclax Story
  Arian Emami Riedmaier1, David J Lindley2, Jeffrey A Hall, Steven Castleberry, Russell T Slade, Patricia Stuart, Robert A Carr, Thomas B Borchardt, Daniel A.J Bow, Marjoleen Nijsen
  J. Pharm. Sci. 107, 495-502 (2018)
  [DOI: 10.1016/j.xphs.2017.09.027] [PDF]
• Bayesian Approach to Establish Bioequivalence: Why and How?
  Carl C. Peck and Gregory Campbell
  Clin. Pharmacol. Therap. 105, 301-303 (2019)
  [DOI: 10.1002/cpt.1288] [PDF]
• On Bayesian Analysis and Hypothesis Testing in the Determination of Bioequivalence
  Donald J. Schuirmann, Stella Grosser, Somesh Chattopadhyay and Shein-Chung Chow
  Clin. Pharmacol. Therap. 105, 304-306 (2019)
  [DOI: 10.1002/cpt.1291] [PDF]
• The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group
  Mirko Koziolek, Stefano Alcaro, Patrick Augustijns, Abdul W. Basit, Michael Grimm, Bart Hens, Caroline L. Hoad, Philipp Jedamzik, Christine M. Madla, Marc Maliepaard, Luca Marciani, Annalisa Maruca, Neil Parrott, Petr Pavek, Christopher J.H. Porter, Christos Reppas, Diana van Riet-Nales, Jari Rubbens, Marina Statelova, Natalie L. Trevaskis, Katerina Valentova, Maria Vertzoni, Dubravka Vitali Cepo, Maura Corsetti
  Eur. J. Pharm. Sci. 134, 31-59 (2019)
  [DOI: 10.1016/j.ejps.2019.04.003] [PDF]
• Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption_ An UNGAP review
  Maria Vertzoni, Patrick Augustijns, Michael Grimm, Mirko Koziolek, Glenn Lemmens, Neil Parrott, Christina Pentafragka, Christos Reppas, Jari Rubbens, Jens Van Den Αbeele, Tim Vanuytsel, Werner Weitschies, Clive G. Wilson
  Eur. J. Pharm. Sci. 134, 153-175 (2019)
  [DOI: 10.1016/j.ejps.2019.04.013] [PDF]
• Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
  Mohamed-Eslam F. Mohamed, Sheryl Trueman, Ahmed A. Othman, Jian-Hwa Han, Tzuchi R. Ju, Patrick Marroum
  AAPS J. 21, 108 (2019)
  [DOI: 10.1208/s12248-019-0378-y] [PDF]
• Physiologically-based pharmacokinetic simulations in pharmacotherapy: selection of the optimal administration route for exogenous melatonin
  Adriana Savoca, Davide Manca
  ADMET & DMPK 7, 44-59 (2019)
  [DOI: 10.5599/admet.625] [PDF]
• PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective
  Cordula Stillhart, Xavier Pepin, Christophe Tistaert, David Good, An Bergh, Neil Parrott, Filippos Kesisoglou
  AAPS J. 21, 19 (2019)
  [DOI: 10.1208/s12248-019-0292-3] [PDF]
• Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
  Jarkko Johansson, Jussi Hirvonen, Zsofia Lovro, Laura Ekblad, Valtteri Kaasinen, Olli Rajasilta, Semi Helin, Jouni Tuisku, Saija Siren, Mirka Pennanen, Arvind Agrawal, Roger Crystal, Petri J. Vainio, Hannu Alho & Mika Scheinin
  Neuropsychopharmacology 44, 1667-1673 (2019)
  [DOI: 10.1038/s41386-019-0368-x] [PDF]
• Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects
  Philip Krieter, C. Nora Chiang, Shwe Gyaw, Phil Skolnick, and Rebekah Snyder
  Drug Metab. Disp. 47, 690-698 (2019)
  [DOI: 10.1124/dmd.118.085977] [PDF]
• Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model
  Chen Xu; Tanran Chang, Yaqi Du; Chaohui Yu, Xin Tan, Xiangdong Li
  Env. Toxicol. Pharmacol. 70, 103202 (2019)
  [DOI: 10.1016/j.etap.2019.103202] [PDF]
• Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function
  Rashmi V. Shingde, Garry G. Graham, Stephanie E. Reuter, Jane E. Carland, Richard O. Day, Sophie L. Stocker
  Ther. Drug Monit. 41, 726-731 (2019)
  [DOI: 10.1097/FTD.0000000000000690] [PDF]
• The Discovery and Development of Liraglutide and Semaglutide
  Lotte Bjerre Knudsen and Jesper Lau
  Front. Endocrinol. 10, 155 (2019)
  [DOI: 10.3389/fendo.2019.00155] [PDF]
• Comparison of Dissolution Profiles and Apparent Permeabilities of Commercially Available Metformin Hydrochloride Tablets in Turkey
  Yagmur Akdag, Tugba Gulsun, Nihan Izat, Levent Oner, and Selma Sahin
  Dissolut. Technol. 27, 22-29 (2020)
  [DOI: 10.14227/DT270120P22] [PDF]
• Zero-order drug delivery: State of the art and future prospects
  Mei-Li Laracuentea, Marina H. Yua, Kevin J. McHugha
  J. Control. Release 327, 834-856 (2020)
  [DOI: 10.1016/j.jconrel.2020.09.020] [PDF]
• A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
  Julie Crockett, David Critchley, Bola Tayo, Joris Berwaerts, Gilmour Morrison
  Epilepsia 61, 267-277 (2020)
  [DOI: 10.1111/epi.16419] [PDF]
• Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen
  Ioannis Loisios-Konstantinidis, Rodrigo Cristofoletti, Nikoletta Fotaki, David B.Turner, Jennifer Dressman
  Eur. J. Pharmaceut. Sci. 143, 205170 (2020)
  [DOI: 10.1016/j.ejps.2019.105170] [PDF]
• Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
  Jeroen Roosendaal, Hilde Rosing, and Jos H. Beijnen
  Clinical Pharmacology in Drug Development 9, 552-559 (2020)
  [DOI: 10.1002/cpdd.840] [PDF]
• Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
  Yan Ji, Ahmed M. Abdelhady, Tanay S. Samant, Shu Yang, and Karen Rodriguez Lorenc
  Clinical Pharmacology in Drug Development 9, 855-866 (2020)
  [DOI: 10.1002/cpdd.853] [PDF]
• Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
  Jeroen Roosendaal, Stefanie L. Groenland, Hilde Rosing, Luc Lucas, Nikkie Venekamp, Bastiaan Nuijen, Alwin D. R. Huitema, Jos H. Beijnen, Neeltje Steeghs
  Eur. J. Clin. Pharmacol. 76, 1075-1082 (2020)
  [DOI: 10.1007/s00228-020-02888-y] [PDF]
• Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial
  Marija Pesic, Frank Schippers, Rob Saunders, Lyn Webster, Martin Donsbach, Thomas Stoehr
  Eur. J. Clin. Pharmacol. 76, 1505-1516 (2020)
  [DOI: 10.1007/s00228-020-02984-z] [PDF]
• Phase 0/microdosing approaches: time for mainstream application in drug development?
  Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama
  Nat. Rev. Drug Discov. 19, 801-818 (2020)
  [DOI: 10.1038/s41573-020-0080-x] [PDF]
• A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach
  H. Markus Weiss, Ken-Ichi Umehara, Veit J. Erpenbeck, Meredith Cain, Janardhana Vemula, Walid Elbast, and Markus Zollinger
  Drug Metabolism and Disposition 48, 917-924 (2020)
  [DOI: 10.1124/dmd.120.090852] [PDF]
• On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food
  Marina Statelova, Konstantinos Goumas, Nikoletta Fotaki, Rene Holm, Mira Symillides, Christos Reppas, Maria Vertzoni
  AAPS J. 22, 6 (2020)
  [DOI: 10.1208/s12248-019-0380-4] [PDF]
• Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods
  Roberto Gomeni, Francoise Bressolle-Gomeni
  AAPS J. 22, 67 (2020)
  [DOI: 10.1208/s12248-020-00445-0] [PDF]
• Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions
  Marina Statelova, Rene Holm, Nikoletta Fotaki, Christos Reppas, Maria Vertzoni
  AAPS J. 22, 126 (2020)
  [DOI: 10.1208/s12248-020-00504-6] [PDF]
• Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension
  Marina Statelova, Rene Holm, Nikoletta Fotaki, Christos Reppas, Maria Vertzoni
  AAPS J. 22, 146 (2020)
  [DOI: 10.1208/s12248-020-00522-4] [PDF]
• A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/ Elbasvir in Healthy Chinese Participants
  Haiyan Li, Zhenhua Yang, Shuang Zhang, Lin Xu, Yudong Wei, Jun Jiang, Luzelena Caro, Hwa-Ping Feng, Jacqueline B McCrea, Meng Li, Shuang Xie, Jiangdian Wang, Xu Min Zhao, Shengmei Mu
  Clin. Pharmacol. 12, 1-11 (2020)
  [DOI: 10.2147/CPAA.S224662] [PDF]
• Biphasic Dissolution as an Exploratory Method during Early Drug Product Development
  Daniela Amaral Silva, Jozef Al-Gousous, Neal M. Davies, Nadia Bou Chacra, Gregory K. Webster, Elke Lipka, Gordon L. Amidon and Raimar Lobenberg
  Pharmaceutics 12, 420 (2020)
  [DOI: 10.3390/pharmaceutics12050420] [PDF]
• BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide
  Milica Markovic, Moran Zur, Inna Ragatsky, Sandra Cvijic and Arik Dahan
  Pharmaceutics 12, 1175 (2020)
  [DOI: 10.3390/pharmaceutics12121175] [PDF]
• Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib
  Shan Jiang, Guoqing Zhang, Lei Wang, Ye Zeng, Wenjie Liu, Zeneng Cheng
  AAPS Pharm. Sci. Tech. 21, 59 (2020)
  [DOI: 10.1208/s12249-019-1612-8] [PDF]
• Predicting human pharmacokinetics from preclinical data: absorption
  Dong-Seok Yim, Suein Choi, and Soo Hyeon Bae
  Transl. Clin. Pharmacol. 28, 126-135 (2020)
  [DOI: 10.12793/tcp.2020.28.e14] [PDF]
• Rapid systemic uptake of naloxone after intranasal administration in children
  Eva Malmros Olsson, Per-Arne Lonnqvist, Carl-Olav Stiller, Staffan Eksborg, Stefan Lundeberg
  Pediatric Anesthesia 00, 1-6 (2021)
  [DOI: 10.1111/pan.14175] [PDF]
• Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs
  Fang Wu, Heta Shah, Min Li, Peng Duan, Ping Zhao, Sandra Suarez, Kimberly Raines, Yang Zhao, Meng Wang, Ho-pi Lin, John Duan, Lawrence Yu, Paul Seo
  AAPS J. 23, 31 (2021)
  [DOI: 10.1208/s12248-021-00564-2] [PDF]
• Lost in modelling and simulation?
  Kiyohiko Sugano
  ADMET & DMPK 9, 75-109 (2021)
  [DOI: 10.5599/admet.923] [PDF]
• Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis-Menten elimination: analytical solution and drug exposure formula
  Xiaotian Wu, Min Chen & Jun Li
  J. Pharmacokin. Pharmacodyn. 48, 495-508 (2021)
  [DOI: 10.1007/s10928-021-09740-5] [PDF]
• An In Vitro-In Vivo Simulation Approach for the Prediction of Bioequivalence
  Marilena Vlachou and Vangelis Karalis
  Materials 14, 555 (2021)
  [DOI: 10.3390/ma14030555] [PDF]
• Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans
  Nadia O. Bamfo, Chelsea Hosey-Cojocari, Leslie Z. Benet, Connie M. Remsberg
  Pharm. Res. 38 1139-1156 (2021)
  [DOI: 10.1007/s11095-021-03076-y] [PDF]
• Scipion PKPD: an Open-Source Platform for Biopharmaceutics, Pharmacokinetics and Pharmacodynamics Data Analysis
  C. O. S. Sorzano, Y. Fonseca-Reyna, M. A. Perez Cruz-Moreno
  Pharm. Res. 38 1169-1178 (2021)
  [DOI: 10.1007/s11095-021-03065-1] [PDF]
• Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis
  Carolina Ameijeiras Rodriguez, Sara Carolina Henriques, Aymara Sancho-Araiz, Inaki F. Troconiz, Luis Almeida, Nuno Elvas Silva
  Pharm. Res. 38 2047-2063 (2021)
  [DOI: 10.1007/s11095-021-03136-3] [PDF]
• Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine
  Mauricio A. Garcia, Rodrigo Cristofoletti, Bertil Abrahamsson, Dirk W. Groot, Alan Parr, James E. Polli, Mehul Mehta, Vinod P. Shah, Tajiri Tomakazu, Jennifer B. Dressman, Peter Langguth
  J. Pharm. Sci. 110 1935-1947 (2021)
  [DOI: 10.1016/j.xphs.2021.02.019] [PDF]
• Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies
  Tycho Heimbach, Filippos Kesisoglou, Jasmina Novakovic, Christophe Tistaert, Martin Mueller-Zsigmondy, Sivacharan Kollipara, Tausif Ahmed, Amitava Mitra, Sandra Suarez-Sharp
  J. Pharm. Sci. 110 3896-2906 (2021)
  [DOI: 10.1016/j.xphs.2021.09.017] [PDF]
• Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
  Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter
  Antimicrobial Agents and Chemotherapy 65 e02428-20 (2021)
  [DOI: 10.1128/AAC.02428-20] [PDF]
• Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose
  Hyun Wook Huh, Young-Guk Na, HeeChol Kang, Minki Kim, Mingu Han, Thi Mai Anh Pham, Hyeonmin Lee, Jong-Suep Baek, Hong-Ki Lee, Cheong-Weon Cho
  Int. J. Pharm. 592, 120113 (2021)
  [DOI: 10.1016/j.ijpharm.2020.120113] [PDF]
• Inclusion complexes of cannabidiol with β-cyclodextrin and its derivative: Physicochemical properties, water solubility, and antioxidant activity
  Hang Li, Sen-Lin Chang, Tan-Ran Chang, Ying You, Xiao-Dong Wang, Li-Wei Wang, Xiao-Fan Yuan, Ming-Hui Tan, Pei-Dong Wang, Peng-Wei Xu, Wei-Bo Gao, Qing-Sheng Zhao, Bing Zhao
  J. Molec. Liquids 334, 116070 (2021)
  [DOI: 10.1016/j.molliq.2021.116070] [PDF]
• Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle
  Wanshan Feng, Chaolong Qin, Elena Cipolla, Jong Bong Lee, Atheer Zgair, Yenju Chu, Catherine A. Ortori, Michael J. Stocks, Cris S. Constantinescu, David A. Barrett, Peter M. Fischer and Pavel Gershkovich
  Pharmaceutics 13, 1349 (2021)
  [DOI: 10.3390/pharmaceutics13091349] [PDF]
• One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products
  Mercedes Prieto-Escolar, Juan J. Torrado, Covadonga Alvarez, Alejandro Ruiz-Picazo, Marta Simon-Vazquez, Carlos Govantes, Jesus Frias, Alfredo Garcia-Arieta, Isabel Gonzalez-Alvarez and Marival Bermejo
  Pharmaceutics 13, 690 (2021)
  [DOI: 10.3390/pharmaceutics13050690] [PDF]
• Metformin doses to ensure efficacy and safety in patients with reduced kidney function
  Isabelle H. S. Kuan, Luke C. Wilson, Jed C. Leishman, Samuel Cosgrove, Robert J. Walker, Tracey L. Putt, John B. W. Schollum, Daniel F. B. Wright
  PLoS ONE 16, e0246247 (2021)
  [DOI: 10.1371/journal.pone.0246247] [PDF]
• The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis
  Kenneth Skov, Niels A. Graudal, Gesche Jürgens
  Basic Clin. Pharmacol. Toxicol. 128, 568-578 (2021)
  [DOI: 10.1111/bcpt.13553] [PDF]
• Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory Perspective
  Lanyan Fang, Ramana Uppoor, Mingjiang Xu, Satish Sharan, Hao Zhu, Nilufer Tampal, Bing Li, Lei Zhang, Robert Lionberger and Liang Zhao
  Clin. Pharmacol. Therap. 110, 880-887 (2021)
  [DOI: 10.1002/cpt.2174] [PDF]
• TDM is dead. Long live TCI!
  Nick Holford, Guangda Ma, David Metz
  Br. J. Clin. Pharmacol. 88, 1406-1413 (2022)
  [DOI: 10.1111//bcp.14434] [PDF]
• Editor's note on the themed issue: integration of machine learning and quantitative systems pharmacology
  Peter L. Bonate
  J. Pharmacokin. Pharmacodyn. 49, 1-3 (2022)
  [DOI: 10.1007/s10928-022-09803-1] [PDF]
• State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
  Giovanni Bocci, Tudor I. Oprea, Leslie Z. Benet
  AAPS J. 24, 37 (2022)
  [DOI: 10.1208/s12248-022-00687-0] [PDF]
• A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic
  Amr Alaarg, Rajeev Menon, David Rizzo, Yemin Liu, Jeffrey Bien, Tricia Elkinton, Timothy Grieme, Lutz R. Asmus, Ahmed Hamed Salem
  Clin. Transl. Sci. 15, 244-254 (2022)
  [DOI: 10.1111/cts.13144] [PDF]
• Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats
  Shun Nakashima, Takeharu Iwamoto, Masashi Takanashi, Ken-ichi Ogawara, Masato Maruyama, Kazutaka Higaki
  Pharm. Res. 39, (2022)
  [DOI: 10.1007/s11095-022-03325-8] [PDF]
• Modeling Drug Dissolution in 3-Dimensional Space
  Chi So, Po-Chang Chiang & Chen Mao
  Pharm. Res. 39, 907-917 (2022)
  [DOI: 10.1007/s11095-022-03270-6] [PDF]
• Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development
  Di Wu, Min Li
  Pharm. Res. 39, (2022)
  [DOI: 10.1007/s11095-022-03373-0] [PDF]
• Modeling of Particle Dissolution Behavior Using a Geometrical Phase-Field Approach
  Dominik Sleziona, David R. Ely, and Markus Thommes
  Molec. Pharmac. 19 3749-3756 (2022)
  [DOI: 10.1021/acs.molpharmaceut.2c00214] [PDF]
• Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development
  Di Wu, Min Li
  Pharm. Res. 39, (2022)
  [DOI: 10.1007/s11095-022-03373-0] [PDF]
• Modeling of Particle Dissolution Behavior Using a Geometrical Phase-Field Approach
  Dominik Sleziona, David R. Ely, and Markus Thommes
  Molec. Pharmac. 19 3749-3756 (2022)
  [DOI: 10.1021/acs.molpharmaceut.2c00214] [PDF]
• A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog
  Yael Shilo-Benjamini, Ahuva Cern, Daniel Zilbersheid, Atara Hod, Eran Lavy, Dinorah Barasch and Yechezkel Barenholz
  Front. Vet. Sci. 9, 892306 (2022)
  [DOI: 10.3389/fvets.2022.892306] [PDF]
• Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol
  Aleksandra Zielinska, Amanda Cano, Tatiana Andreani, Carlos Martins-Gomes, Amelia M. Silva, Marlena Szalata, Ryszard Slomski and Eliana B. Souto
  Int. J. Mol. Sci. 23, 6165 (2022)
  [DOI: 10.3390/ijms23116165] [PDF]
• Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen
  I. Camara-Martinez, J.A. Blechar, A. Ruiz-Picazo, A. Garcia-Arieta, C. Calandria, V. Merino-Sanjuan, P. Langguth, M. Gonzalez-Alvarez, M. Bermejo, J. Al-Gousous, I. Gonzalez-Alvarez
  Int. J. Pharm. 614, 121415 (2022)
  [DOI: 10.1016/j.ijpharm.2021.121415] [PDF]
• Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation?
  Mahmoud Azzeh, Marco Battaglia, Simon Davies, John Strauss, Prashant Dogra, Venkata Yellepeddi
  Int. J. Clin. Pharmacol. Ther. 60, 253-263 (2022)
  [DOI: 10.5414/CP204217] [PDF] [Supplementary Information]
• An Analytical Solution for Saturable Absorption in Pharmacokinetics Models
  C.O.S. Sorzano, M.A. Perez-de-la-Cruz Moreno, J.L. Vilas
  Pharm. Res. 39, (2022)
  [DOI: 10.1007/s11095-022-03455-z] [PDF]
• A Novel faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
  Tair Lapidot, Mohammed Bouhajib, Janice Faulknor, Shabaz Khan, Galia Temtsin Krayz, Carolina Abrutzky, Dalia Megiddo
  Pharm. Res. 39, 963-975 (2022)
  [DOI: 10.1007/s11095-022-03247-5] [PDF]
• Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
  José L. Calvo-Gallego, Peter Pivonka, Rocío Ruiz-Lozano and Javier Martinez-Reina
  Front. Bioeng. Biotechnol. 10, 940620 (2022)
  [DOI: 10.3389/fbioe.2022.940620] [PDF]
• Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
  Qingxia Liu, Huiping Huang, Baohua Xu, Dandan Li, Maobai Liu, Imam H. Shaik and Xuemei Wu
  Pharmaceutics 14, 1004 (2022)
  [DOI: 10.3390/pharmaceutics14051004] [PDF]
• Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study
  Da Young Lee, Soyoung Shin, Tae Hwan Kim and Beom Soo Shin
  Pharmaceutics 14, 1226 (2022)
  [DOI: 10.3390/pharmaceutics14061226] [PDF]
• Cyclodextrin-Based Nanosponges: Overview and Opportunities
  Gianluca Utzeri, Pedro M. C. Matias, Dina Murtinho and Artur J. M. Valente
  Front. Chem. 10, 859406 (2022)
  [DOI: 10.3389/fchem.2022.859406] [PDF]
• Estimating and Assessing Differential Equation Models with Time-Course Data
  Samuel W. K. Wong, Shihao Yang, and S. C. Kou
  J. Phys. Chem. B 127, 2362-2374 (2023)
  [DOI: 10.1021/acs.jpcb.2c08932] [PDF] [Supporting Information]
• Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly
  Sarina Tanimoto, Michael Kaliner, Richard F. Lockey, Motohiro Ebisawa, Luana Pesco Koplowitz, Barry Koplowitz, Richard Lowenthal
  Ann. Allergy Asthma Immunol. 130, 508-514 (2023)
  [DOI: 10.1016/j.anai.2022.10.024] [PDF]
• The Uses and Advantages of Kirchhoff's Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry
  Leslie Z. Benet, Jasleen K. Sodhi
  AAPS J. 25, 38 (2023)
  [DOI: 10.1208/s12248-023-00801-w] [PDF]
• Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
  Roberto Gomeni & Francoise Bressolle-Gomeni
  J. Pharmacokin. Pharmacodyn. 50, 89-96 (2023)
  [DOI: 10.1007/s10928-022-09835-7] [PDF]
• Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery
  Mitesh Patel, Julia Riede, Dallas Bednarczyk, Birk Poller, Sujal V. Deshmukh
  Pharm. Res. 40, 937-949 (2023)
  [DOI: 10.1007/s11095-023-03482-4] [PDF] [Supplementary Information]
• In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature
  Sherin Thomas, Dana C. Hammell, Hazem E. Hassan, Audra L. Stinchcomb
  Pharm. Res. 40, 1249-1258 (2023)
  [DOI: 10.1007/s11095-023-03487-z] [PDF]
• A novel method to estimate the absorption rate constant for two-compartment model fitted drugs without intravenous pharmacokinetic data
  Fan Liu, Hanxi Yi, Lei Wang, Zeneng Cheng, Guoqing Zhang
  Front. Pharmacol. 14, (2023)
  [DOI: 10.3389/fphar.2023.1087913] [PDF]
• The influence of flip-flop in population pharmacokinetic analyses
  Isabelle H. S. Kuan, Daniel F. B. Wright, Stephen B. Duffull
  CPT Pharmacometrics Syst. Pharmacol. 12, 285-287 (2023)
  [DOI: 10.1002/psp4.12909] [PDF]
• Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics
  Kazuko Sagawa, Jian Lin, Rohit Jaini, Li Di
  Pharm. Res. 40, 1927-1938 (2023)
  [DOI: 10.1007/s11095-023-03538-5] [PDF] [Supplementary Information]
• Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict
  Gopal Pawar, Fang Wu, Liang Zhao, Lanyan Fang, Gilbert J. Burckart, Kairui Feng, Youssef M. Mousa, Abdullah Al Shoyaib, Marie-Christine Jones, Hannah K. Batchelor
  AAPS J. 25, 67 (2023)
  [DOI: 10.1208/s12248-023-00826-1] [PDF]
• Preclinical Bioavailability Assessment of a Poorly Water-Soluble Drug, HGR4113, Using a Stable Isotope Tracer
  Eun Ji Ha, Jeong In Seo, Shaheed Ur Rehman, Hyung Soon Park, Sang-Ku Yoo and Hye Hyun Yoo
  Pharmaceutics 15, 1684 (2023)
  [DOI: 10.3390/pharmaceutics15061684] [PDF]
• Factors Influencing the Selection of Medium for Evaluating Drug Solubility and Dissolution in Bovine Milk
  Marilyn N. Martinez, David Longstaff, Vivek Fellner, and Martin Coffey
  Dissolut. Technol. 30, 134-142 (2023)
  [DOI: 10.14227/DT300323P134] [PDF]
• Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
  Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A. Suleiman, Sven Mensing, Anette Koenigsdorfer, Julia Teresa Schiele, Tammy Palenski, Divya Samineni, David Hoffman, Rajeev Menon & Ahmed Hamed Salem
  Clin. Drug Investig. 42, 657-668 (2023)
  [DOI: 10.1007/s40261-022-01172-4] [PDF]
• Impact of tablet crushing on the dissolution of venetoclax
  Takeo Yasu, Eri Hikita, Yoshito Gando, Moyumi Odate, Motoki Inoue & Mikio Shirota
  Ann. Hematol. 102, 219-220 (2023)
  [DOI: 10.1007/s00277-022-05014-3] [PDF]
• Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor
  Ahmed Hamed Salem, Rajeev M. Menon
  Clin. Transl. Sci. 17, e13807 (2023)
  [DOI: 10.1111/cts.13807] [PDF]
• Notes on the Use of Kirchhoff's Laws in Pharmacokinetics
  Ronald A. Siegel
  AAPC J. 26, 8 (2024)
  [DOI: 10.1208/s12248-024-00875-x] [PDF]
• Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products
  Fang Wu, Youssef Mousa, Rebeka Jereb, Hannah Batchelor, Sumon Chakraborty, Tycho Heimbach, Ethan Stier, Filippos Kesisoglou, Sivacharan Kollipara, Lei Zhang, Liang Zhao
  AAPC J. 26, 19 (2024)
  [DOI: 10.1208/s12248-024-00886-x] [PDF]
• An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing
  Hirokazu Wakuda, Yue Xiang, Jasleen K. Sodhi, Naoto Uemura, Leslie Z. Benet
  AAPC J. 26, 22 (2024)
  [DOI: 10.1208/s12248-024-00887-w] [PDF]
• Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling
  José Ricardo Arteaga-Bejarano, Santiago Torres
  J. Pharmacokin. Pharmacodyn. 51, (2024)
  [DOI: 10.1007/s10928-024-09920-z] [PDF]
• Importance of Considering Fed-State Gastrointestinal Physiology in Predicting the Reabsorption of Enterohepatic Circulation of Drugs
  Kohei Nakamura, Atsushi Kambayashi, Satomi Onoue
  Pharm. Res. 41, 673-685 (2024)
  [DOI: 10.1007/s11095-024-03669-3] [PDF]
• Formulation and Validation of an Extended Sigmoid Emax Model in Pharmacodynamics
  Jong Hyuk Byun
  Pharm. Res. 41, 1787-1795 (2024)
  [DOI: 10.1007/s11095-024-03752-9] [PDF]
• Novel analytical solutions for convolution in compartmental pharmacokinetic models and application to non-bioequivalent formulations
  Mauricio A. García, Pablo M. González, Alexis Aceituno, Jozef Al-Gousous
  Eur. J. Pharm. Sci. 201, (2024)
  [DOI: 10.1016/j.ejps.2024.106892] [PDF]
• Development of venetoclax with 2-hydroxypropyl-beta-cyclodextrin inclusion complex for improved bioavailability
  EurJPharmSci_202(2024)106892til Smalant Kishor, Chary Padakanti Sandeep, Maddipatla Sarvan, Madhavi Y.V, Singothu Siva, Bhandari Vasundhra, Pardhi Ekta, Bansal Kuldeep Kumar, Mehra Neelesh Kumar
  J. Biomol. Struct. Dyn. 201, 1-18 (2024)
  [DOI: 10.1080/07391102.2024.2305695] [PDF]

Interesting links

• ClinicalTrials.gov: Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone (FDA/Spaulding Clinical Research LLC)
• FDA, Bioequivalence Requirements and In Vivo Bioavailability Procedures, Federal Register 42 (1), 1624-1653 (1977) [source, PDF]
• FDA. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations (2014) [https://www.gmp-compliance.org/files/guidemgr/UCM389370.pdf] [also here]
• EMA ICH M9 guideline on biopharmaceutics classification system-based biowaivers Step 5 [also here]
• EMA, CHMP: Guideline on the investigation of bioequivalence (2010) [also here]
• EMA: Draft on AI in the medicinal product lifecycle (2023) [also here]
• Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry by FDA/CDER/ Purdie, Florine P [also here]
• PubMed

• A contribution to the mathematical theory of epidemics
  William Ogilvy Kermack and A. G. McKendrick
  Proc. R. Soc. Lond. A 115, 700-721 (1927)
  [DOI: 10.1098/rspa.1927.0118] [PDF]
• Contributions to the mathematical theory of epidemics. II. -The problem of endemicity
  William Ogilvy Kermack and A. G. McKendrick
  Proc. R. Soc. Lond. A 138, 55-83 (1932)
  [DOI: 10.1098/rspa.1932.0171] [PDF]
• Science and Statistics
  George E. P. Box
  J. Am. Stat. Assoc. 71, 791-799 (1976)
  [DOI: 10.2307/2286841] [PDF]
• Fractal Reaction Kinetics
  Raoul Kopelman
  Science 241, 1620 (1988)
  [DOI: 10.1126/science.241.4873.1620] [PDF]
• On the definition and the computation of the basic reproduction ratio R₀ in models for infectious diseases in heterogeneous populations
  O. Diekmann, J. A. P. Heesterbeek & J. A. J. Metz
  J. Math. Biol. 28, 365-382 (1990)
  [DOI: 10.1007/BF00178324] [PDF]
• A Brief History of R₀ and a Recipe for its Calculation
  J. A. P. Heesterbeek
  Acta Biotheor. 50, 189-204 (2002)
  [DOI: 10.1023/A:1016599411804] [PDF]
• Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic
  Niall P. A. S. Johnson and Juergen Mueller
  Bulletin of the History of Medicine 76, 105-115 (2002)
  [URL: https://www.jstor.org/stable/44446153] [PDF]
• Notes on R0
  James Holland Jones
  (2007)
  [PDF]
• Mathematical models of infectious disease transmission
  Nicholas C. Grassly and Christophe Fraser
  Nat. Rev. Microbiol. 6, 477-487 (2008)
  [DOI: 10.1038/nrmicro1845] [PDF]
• An Introduction to The Basic Reproduction Number in Mathematical Epidemiology
  Antoine Perasso
  ESAIM: Proceedings and Surveys 62, 123-138 (2018)
  [DOI: 10.1051/proc/201862123] [PDF]
• Complexity of the Basic Reproduction Number (R₀)
  Paul L. Delamater, Erica J. Street, Timothy F. Leslie, Y. Tony Yang, and Kathryn H. Jacobsen
  Emerg. Infect. Dis. 25, 1 (2019)
  [DOI: 10.3201/eid2501.171901] [PDF]
• Some fractal thoughts about the COVID-19 infection outbreak
  Massimo Materassi
  Chaos, Solitons & Fractals: X 4, 100032 (2019)
  [DOI: 10.1016/j.csfx.2020.100032] [PDF]
• Predictive Mathematical Models of the COVID-19 Pandemic: Underlying Principles and Value of Projections
  Nicholas P. Jewell, Joseph A. Lewnard, Britta L. Jewell
  JAMA 323, 1893-1894 (2020)
  [DOI: 10.1001/jama.2020.6585] [PDF]
• Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
  Laure Wynants, Ben Van Calster, Gary S Collins, Richard D Riley, Georg Heinze, Ewoud Schuit, Marc M J Bonten, Darren L Dahly, Johanna A Damen, Thomas P A Debray, Valentijn M T de Jong, Maarten De Vos, Paula Dhiman, Maria C Haller, Michael O Harhay, Liesbet Henckaerts, Pauline Heus, Michael Kammer, Nina Kreuzberger, Anna Lohmann, Kim Luijken, Jie Ma, Glen P Martin, David J McLernon, Constanza L Andaur Navarro, Johannes B Reitsma, Jamie C Sergeant, Chunhu Shi, Nicole Skoetz, Luc J M Smits, Kym I E Snell, Matthew Sperrin, Rene Spijker, Ewout W Steyerberg, Toshihiko Takada, Ioanna Tzoulaki, Sander M J van Kuijk, Bas C T van Bussel, Iwan C C van der Horst, Florien S van Royen, Jan Y Verbakel, Christine Wallisch, Jack Wilkinson, Robert Wolff, Lotty Hooft, Karel G M Moons, Maarten van Smeden
  BMJ 369, m1328 (2020)
  [DOI: 10.1136/bmj.m1328] [PDF]
• Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China
  Benjamin F. Maier and Dirk Brockmann
  Science 368, 742-746 (2020)
  [DOI: 10.1126/science.abb4557] [PDF]
• An analysis of COVID-19 spread based on fractal interpolation and fractal dimension
  Cristina-Maria Pacurar, Bogdan-Radu Necula
  Chaos, Solitons & Fractals 139, 110073 (2020)
  [DOI: 10.1016//j.chaos.2020.110073] [PDF]
• On the use of growth models to understand epidemic outbreaks with application to COVID-19 data
  Chénangnon Frédéric Tovissodé, Bruno Enagnon Lokonon, Romain Glèlè Kakai
  PLOS One 15, e0240578 (2020)
  [DOI: 10.1371/journal.pone.0240578] [PDF]
• Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak
  Sang Woo Park, Benjamin M. Bolker, David Champredon, David J. D. Earn, Michael Li, Joshua S. Weitz, Bryan T. Grenfell, and Jonathan Dushoff
  J. R. Soc. Interface 17, 20200144 (2020)
  [DOI: 10.1098/rsif.2020.0144] [PDF]
• Estimation of the basic reproduction number (R0) for the novel coronavirus disease in Sri Lanka
  Samath Dharmaratne, Supun Sudaraka, Ishanya Abeyagunawardena, Kasun Manchanayake, Mahen Kothalawala and Wasantha Gunathunga
  Virology J. 17, 144 (2020)
  [DOI: 10.1186/s12985-020-01411-0] [PDF]
• COVID-19, flattening the curve, and Benford's law
  Kang-Bok Lee, Sumin Han, Yeasung Jeong
  Physica A 559, 125090 (2020)
  [DOI: 10.1016/j.physa.2020.125090] [PDF]
• Burden and characteristics of COVID-19 in the United States during 2020
  Pei Sen, Teresa K. Yamana, Sasikiran Kandula, Marta Galanti & Jeffrey Shaman
  Nature 598, 338-341 (2021)
  [DOI: 10.1038/s41586-021-03914-4] [PDF]
• Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave
  Jessica T. Davis, Matteo Chinazzi, Nicola Perra, Kunpeng Mu, Ana Pastore y Piontti, Marco Ajelli, Natalie E. Dean, Corrado Gioannini, Maria Litvinova, Stefano Merler, Luca Rossi, Kaiyuan Sun, Xinyue Xiong, Ira M. Longini, M. Elizabeth Halloran, Cecile Viboud, Alessandro Vespignani
  Nature 600, 127-132 (2021)
  [DOI: 10.1038/s41586-021-04130-w] [PDF]
• The analysis of a fractional network-based epidemic model with saturated treatment function and fuzzy transmission
  N. P. Dong, H. V. Long and N. T. K. Son
  Iranian J. Fuzzy Systems 20, 1-18 (2023)
  [DOI: 10.22111/IJFS.2023.7342] [PDF]

• Papers and patents are becoming less disruptive over time
  Michael Park, Erin Leahey, Russell J. Funk
  Nature 613, 138-144 (2023)
  [DOI: 10.1038/s41586-022-05543-x] [PDF]
• ICH Reflection paper on proposed international harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines
  EMA Committee for Human Medicinal Products
  [EMA] [PDF] [Comments]